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1. SUMMARY 
Bone is a dynamic, vascularised tissue with a unique capacity to heal and remodel without 
leaving a scar. (Sommerfeldt DW 2001) These properties, together with its capacity to rapidly 
mobilize mineral stores on metabolic demand, make it the ultimate smart material. Its main 
role is to provide structural support for the body. Furthermore the skeleton also serves as a 
mineral reservoir, supports muscular contraction resulting in motion, withstands load bearing 
and protects internal organs. (Sommerfeldt DW 2001 ,Rodan GA 1992) Hence, it is logical to say 
that major alterations in its structure due to injury or disease can dramatically alter one’s body 
equilibrium and quality of life. In fact, when the dimension of a lesion overcomes the intrinsic 
regenerative capacity of bone or when patient related conditions, such as infections, 
inadequate blood supply or systemic diseases impair bone healing, tissue transplants or 
biomaterials are necessary to support, stimulate and accelerate the bone ingrowth. 
Annually, more than 2.2 million bone grafting procedures are performed worldwide. 
(Giannoudis PV 2005) The current gold standard for bone repair is the use of autologous bone 
grafts harvested from a remote site in the patient. A few of the many problems associated with 
autografts include donor site morbidity and the restricted availability.(De Long WG 2007) In 
addition to autografts, success has been reported with the use of allografts. Like the autografts, 
allografts are limited in supply and risks of disease transmission and immune rejection exist. 
Despite the benefits of both autografts and allografts, the relative concerns over their use have 
led to the development of numerous synthetic bone substitutes. Moreover, biomaterials play 
central roles in modern strategies in regenerative medicine and tissue engineering as 
designable biophysical and biochemical milieus that direct cellular behavior and function. 
(Langer R 2004) The guidance provided by biomaterials may facilitate restoration of structure 
and function of damaged or dysfunctional tissues, both in cell-based therapies, such as those 
where biomaterials as scaffolds or carriers deliver transplanted cells or matrices induce 
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morphogenesis in bioengineered tissues constructed ex vivo, and in a-cellular therapies, such as 
those where materials induce recruitment, ingrowth and differentiation of cells from healthy 
residual tissues in situ. Such materials should provide a provisional three-dimensional (3-D) 
support to interact bio-molecularly with cells to control their function, guiding the spatially and 
temporally complex multicellular processes of tissue formation and regeneration.  
Both biologically derived and synthetic materials have been extensively explored in 
regenerative medicine and tissue engineering. In general, materials from biological sources 
(e.g., purified protein components such as collagens from animal tissues) are advantageous 
because of their inherent properties of biological recognition, including presentation of 
receptor-binding ligands and susceptibility to cell-triggered proteolytic degradation and 
remodelling. Despite these advantages, many issues have spurred the development of synthetic 
biomaterials as cellular substrates, including complexities associated with purification, 
immunogenicity and pathogen transmission. Although some of these limitations can be 
overcome by recombinant protein expression technologies, greater control over materials 
properties and tissue responses could be achieved where synthetic analogs are available. 
One of the most promising group of synthetic bone substitutes are calcium phosphate ceramics 
(CaPs). The most commonly used CaPs are hydroxyapatite (HA) and tricalcium phosphate (TCP) 
or an intrinsic combination of the two. (LeGeros RZ 2002, LeGeros RZ 2003)  
Biocompatibility, bioactivity, and easiness to adapt to the shape of bone cavities and defects 
are some of the reasons of the increasing interest towards CaPs application in both medical and 
dental surgery. Preclinical and clinical studies demonstrate the effectiveness of HA and TCP for 
the treatment of bone defects because of trauma or surgery. (Mann RJ 2011, Martini L 2011, 
Fini M 2006,Fini M 2000, Fini M 2002, Calvo-Guirado JL 2011, Pinto JG 2011, Frota R 2011) TCP 
is also proposed as bone cement associated to poly-methylmethacrylate (PMMA), the most 
widely employed material for implant fixation, for the improvement of PMMA biocompatibility. 
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(Fini M 2002, Ginebra MP 2001) A further advantage of CaPs with respect to PMMA is the 
absence of heat development during hardening. Mixing of a CaPs powder with an aqueous 
solution leads to the hardening of the cement paste through a low temperature 
dissolution/precipitation reaction. The lack of an exothermic reaction is desirable not only to 
avoid inflammatory tissue response, but also for potential employment of the cements for the 
delivery of sensitive molecules such as drugs or proteins. 
Many strategies exist in order to improve bone lesion treatment and drugs or ion scan be used 
in association with ceramic materials to accelerate bone repair and remodelling. 
Bisphosphonates (BPs) are a chemical class of compounds in widespread use since the 1970s 
for the management of disorders of bone metabolism, associated to bone loss. These 
compounds bind strongly to HA crystals, they suppress osteoclast-mediated bone resorption, 
they are retained for a long time in the skeleton, and they are excreted un-metabolized in 
urine. (Papapoulos SE 2006) Also strontium (Sr), that is present in the mineral phase of bone, 
has the ability to enhance bone volume and prevent bone loss. (Marie PJ 2007) Furthermore, Sr 
administration as Sr ranelate has recently been shown to reduce the incidence of fractures in 
osteoporotic patients. (Ammann P 2005) Sr exerts both anti-resorbing and bone forming effects 
in vitro, because it increases the number of osteoblasts and decreases the number and the 
activity of osteoclasts. (Canalis E 1996) 
The aims of this research, in collaboration with the Department of Chemistry, “G. Ciamician”, 
Bologna University were: 
1) to manufacture a biomimetic gelatin- calcium phosphate bone cement and to carry out the 
preclinical biological studieson healthy bone defects; 
2) to develop an Alendronate (AL)- HA nanocomposite material prepared using different 
concentrations of AL and a Sr- HA nanocrystal prepared from solutions containing different 
4 
 
concentrations of Sr atom and to carry out preclinical biological studies on healthy and 
osteoporotic bone. 
Preclinical biological studies were aimed to evaluate: 
-in vitro and in vivo biocompatibility (following Organization of Standardization (ISO) guides 
10993); 
-effects on bone cell behavior; 
-preclinical effectiveness in bone defects and in healing of bone in osteoporosis conditions. 
Following a biomimetic strategy aimed to reproducing bone characteristics, the first aim of this 
thesis was to investigate the biological properties of new gelatin enriched calcium phosphate 
cement (GEL-CP) that exhibits improved mechanical properties with respect to the cement 
prepared without gelatin (C-CP) and to HA. For this purpose we cultured human osteoblast 
MG63 on GEL-CP as compared with cells cultured on C-CP and HA sample. Cell attachment, 
proliferation and differentiation were evaluated up to 21 days. SEM analyses revealed that 
osteoblasts grown on GEL-CP showed a normal morphology and biological tests demonstrated 
very good rate of proliferation and viability at each experimental time. The presence of gelatin 
stimulated alkaline phosphatase activity, collagen I and transforming growth factor ß1 
production. This in vitro data indicate that the new cement GEL-CP favors osteoblast 
proliferation, activation of their metabolism and differentiation. These data have led to believe 
that GEL-CP could be a promising biomimetic material to be successfully applied as bone 
substitute. To this purpose, an in vivo investigation was performed on healthy rabbits, in order 
to perform histological, histomorphometrical and microtomographical analyses on bone 
healing rate and osseointegration of these materials. Our results showed that at both 4-weeks 
and 12-weeks after surgery HA implant had significantly higher value of healing rate than GEL-
CP implant. No differences were found in osseointegration index between C-CP, GEL-CP and HA 
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groups. These in vivo results have allowed to detect that an improvement in the structure of 
this novel material would lead to a greater upgrading in the in vivo experimental results.  
The second aim of this thesis was to evaluate an HA nanocrystals synthesized at different 
extent of Sr substitution for calcium and an HA-AL nanocrystals synthesized at increasing AL 
content. HA nanocrystals were synthesized at Sr contents of 0, 1, 3, 7 atom %. Sr incorporation 
for calcium (Ca) was confirmed by the linear increase of the unit cell parameters of HA, in 
agreement with the different ionic radii of the two ions. Moreover, Sr substitution slightly 
affected HA structural order and the shape of the nanocrystals. Osteoblast-like MG63 cells 
cultured on the nanocrystals showed good proliferation and increased values of the 
differentiation parameters. In particular, when cultured on samples with Sr concentration in 
the range 3–7 atom %, osteoblasts demonstrated an increased values of alkaline phosphatase 
activity, collagen type I, and osteocalcin production. Moreover, osteoclast number on all the Sr-
doped samples was significantly smaller than that on HA, and it decrease on increasing Sr 
content. 
Regarding, the synthesis of HA in the presence of BPs we developed a new method which 
allowed to synthesize AL–HA composite nanocrystals with a BPs content up to about 7 wt%. 
Subsequently, we carried out an in vitro study aimed to investigate the effects of AL 
incorporation into HA on bone cells response. Osteoblast-like MG63 cells and human 
osteoclasts were cultured on HA nanocrystals at different AL content. MG63 cells cultured on 
the composite nanocrystals showed normal morphology, good proliferation and increased 
values of the differentiation parameters. In particular, when cultured on composites at 
relatively high AL contents, osteoblasts demonstrated an increased values of alkaline 
phosphatase activity, collagen type I, and osteocalcin production, as well as significant decrease 
of matrix metalloproteinases production, with respect both to the control and to pure HA 
nanocrystals. The presence of AL enhances osteoblast activation and extracellular matrix 
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mineralization processes, without any abnormal collagen degradation. Moreover, the 
osteoclast number on the composite nanocrystals decreased indicating that the BPs exerts its 
inhibitory effect on osteoclast proliferation even when incorporated into HA. 
These in vitro data on HA nanocrystals synthesized at different extent of Sr and AL indicated 
that Sr and AL stimulated osteoblast activity and exerted its inhibitory effect on osteoclast 
proliferation. 
These results suggest that Sr-doped HA and AL-doped HA can be usefully employed for the 
preparation of biomaterials capable to promote osseointegration and bone regeneration, and 
for local prevention/repair of bone loss. 
Based on our in vitro data we carried out an in vivo study in which the experimental 
biomaterials (HA, SrHA5%, SrHA10%, HA-AL7, HA-AL28) were implanted in lumbar spine, 
between the transverse processes of L4 and L5 vertebrae, of healthy and osteoporotic female 
rats. Osteoporosis condition was obtained by the use of ovariectomized animals that were 
recognized to be a model for estrogen depletion and osteoporosis. (Davidge ST 2001) Eight 
weeks after material implantation the bone segment were explanted and analyzed by 
histological, histomorphometrical and microtomographical analyses. The histological, 
histomorphometrical and microtomographical tests showed that in healthy bone HA was the 
best material presenting higher values of bone volume and bone surface when compared with 
all the other experimental materials. Contrary, in osteoporotic bone HA presented the lower 
values of bone volume and bone surface when compared with the other materials. In 
osteoporotic bone HA-AL28 material revealed the higher values of bone volume and bone 
surface compared with the other experimental materials.  
In agreement with our in vitro results, our in vivo model showed that HA-AL 28 was a 
remarkably effective inhibitor of bone resorption in comparison to HA-Sr5%, HA-Sr10% and HA. 
Moreover, these results have allowed to detect that HA is an ideal carrier of BPs; HA loaded 
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with appropriate concentration of AL may be ideal for use in spinal fusion of osteoporotic 
subjects. 
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2. BONE BIOLOGY 
2.1 The Skeleton 
The skeleton is a highly specialized organ that has several functions. It maintains the shape of 
the body, shields vital organs from external insults, serves as a scaffold for the muscles allowing 
their contraction to be translated into bodily movement, resists mechanical load during 
locomotion and weight bearing, and provides a reservoir of Ca, Mg, bicarbonate and 
phosphate. The skeleton consists of mineralized and un-mineralized connective tissue matrix, 
highly specialized cells, and spaces that include the bone marrow cavity, vascular canals, 
canaliculi, and lacunae. 
Bones are characterized anatomically as long bones (i.e. humerus, femur), flat bones 
(membrane bones) and irregular bones (such as the vertebrae). The main shaft of long bones is 
called the diaphysis. At the extremities of the long bone are the epiphyses (in articulating 
joints). The region involved in bone elongation between the diaphysis and epiphysis in growing 
bones is called the metaphysis. The architecture of the skeleton has two different structures: 
cortical and cancellous (Figure 1). Cortical bone forms the solid outer wall of all bones and 
accounts for about 80% of bone mass. Cancellous bone consists of a three-dimensional network 
of trabeculae located mainly in the metaphysis and epiphysis of long bones such as the femur 
and inside of flat bones such as the ileum and cranium. Cancellous, or trabecular, bone is in 
intimate contact with the hematopoietic bone marrow and accounts for 20% of the total bone 
mass. The collagen architecture of bone can be either lamellar or woven. Unlike the highly 
organized lamellar bone architecture of normal adult cortical and trabecular bone, woven bone 
lacks oriented collagen fibers.  
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a                b  
 
Figure 1: Histological section of a) trabecular bone and b) cortical bone. Fast Green staining. 
Magnification 10x.(Histological images from the Laboratory of Preclinical and Surgical Studies 
and from Laboratory of Biocompatibility, Technological Innovations and Advanced Therapies, 
Rizzoli Research Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy). 
 
Bones are covered with a connective tissue called the periosteum (absent from the articular 
cartilage surfaces). A thinner layer of connective tissue, known as the endosteum, surrounds 
the bone marrow spaces and trabeculae of spongy bone. The periosteum and endosteum are a 
source of new bone-forming cells (osteoprogenitor cells) and are described as possessing 
osteogenic potential. The periosteum and endosteum are also involved in bone repair after 
injury. Blood vessels of the periosteum and endosteum are involved in nutrition of the bone.   
From a microscopic point of view, cells constitute only a very small percentage of the bone 
tissue, whereas the bulk of the tissue is occupied by the intercellular, calcified bone matrix. The 
bone matrix has two main components: organic matrix and inorganic salts (Figure 2). 
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Figure 2: Bone tissue composition: cells and extracellular matrix (organic and inorganic).A: 
Osteoblast (Ob); B: Osteoclast (Oc), Osteocytes (Os). Hematossilin & Eosin staining 
Magnification 20x. (Histological images from Laboratory of Preclinical and Surgical Studies and 
from Laboratory of Biocompatibility, Technological Innovations and Advanced Therapies, Rizzoli 
Research Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy). 
 
The organic matrix is composed of type I collagen fibers (about 95%) embedded in an 
amorphous ground substance consisting of sulfated glycosaminoglycans (GAG: chondroitin-4-
sulfate, chondroitin-6-sulfate, keratan sulfate) and various non collagenic bone proteins (bone 
sialoprotein, osteocalcin, …).  
The main Ca deposits in the bone matrix are in the form of crystals of HA Ca10(PO4)6(OH)2; bone 
mineral contains significant amounts of the citrate ion C6H5O7
3- and the carbonate ion CO3
2-, 
and the presence of the fluoride ion F- is common in apatite crystals. Mg and Na are also 
present. 
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2.2 Bone cells 
Actively growing bone contains cells of two different lineages: 
1. The osteoblast lineage, which includes the osteoprogenitor cells and derived osteoblast 
and osteocyte; 
2. The osteoclast lineage. 
Osteoprogenitor cells are of mesenchymal origin and have the properties of stem cells: the 
potential for proliferation and the capacity to differentiate. 
Osteoprogenitor cells give rise to osteoblasts by a regulatory mechanism involving growth and 
transcription factors and are present in the inner layer of the periosteum and endosteum. 
Osteoprogenitor cells persist throughout postnatal life as bone-lining cells; they are reactivated 
in the adult during the repair of bone fractures and other injuries. 
Osteoblast differentiates into osteocyte after they are trapped inside lacunae within the 
mineralized matrix they produce. They differentiation involves the participation of two 
transcription factors: Cbfa/Runx2 and osterix. 
The osteoclast lineage derives from the monocyte-macrophage lineage in the bone marrow. 
2.2.1 Osteoblasts and osteocytes 
Osteoblasts are epithelial-like cells with cuboidal or columnar shapes, forming a monolayer 
covering all sites of active bone formation. They are highly polarized cells: they deposit osteoid, 
the non-mineralized organic matrix of the bone, along the osteoblast-bone interface. 
Osteoblasts initiate and control the subsequent mineralization of osteoid. In electron 
micrographs, osteoblasts display the typical features of cells actively engaged in protein 
synthesis, glycosylation, and secretion (Figure3). Their specific products are type I collagen, 
osteocalcin, osteopontin and bone sialoprotein. Osteoblasts give a strong cytochemical reaction 
for alkaline phosphatase that disappears when the cells become embedded in the matrix as 
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osteocytes. In addition, osteoblasts produce growth factors, in particular members of the bone 
morphogenetic protein family, with bone-inductive activities. 
When bone formation is completed, osteoblasts flatten out and transform into osteocytes 
(Figure 4). Osteocytes are highly branched cells with their body occupying small spaces 
between lamellae, called lacunae. Small channels, the canaliculi, course through the lamellae 
and interconnect neighboring lacunae. Adjacent cells processes, found within canaliculi, are 
connected by gap junctions. Nutrient materials diffuse from neighboring blood vessels, within 
the haversian canal, through the canaliculi into the lacunae. The dense network of osteocytes 
depends not only on intracellular communication across gap junction but also on the 
mobilization of nutrients and signaling molecules along the extracellular environment 
facilitated by canaliculi running from lacuna to lacuna.The life of an osteocyte depends on this 
nutrient diffusion process and the life of the bone matrix depends on the osteocyte. Osteocytes 
can remain alive for years provided vascularization is continuous. 
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Figure3: Osteoblast. Coloured scanning electron micrograph of a bone-making osteoblast cell 
surrounded by a dense network of collagen fibres. The numerous filipodia on the cell surface 
project into the surrounding matrix and maintain contact with other osteoblasts. Magnification: 
x2200 at 5x7cm size. (Images fromCNRI/SCIENCE PHOTO LIBRARY). 
 
 
 
 
 
 
Figure 4: Osteocyte.False-colour scanning electron micrograph of human bone showing an 
osteocyte lying in a cavity known as a lacuna. Magnification: x3200 at 6x7cm size. (Images from 
CNRI/SCIENCE PHOTO LIBRARY). 
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2.2.2 Osteoclasts 
Osteoclasts derive from monocyte-macrophage progenitor cell lineage in the bone marrow, 
which diverges into the osteoclast progenitor pathway (Figure 5). 
The osteoclasts precursor cells are monocytes, which reach the bone through the blood 
circulation and fuse into multinucleated cells with as many as 30 nuclei to form osteoclasts by a 
process regulated by osteoblasts and stromal cells of the bone marrow. 
After attachment to the target bone matrix, osteoclasts generate a secluded acid environment 
required for bone resorption.Bone resorption involves first the dissolution of the inorganic 
components of the bone (bone demineralization) mediated by H+-ATPase (adenosine 
triphosphatase) within an acid  environment, followed by enzymatic degradation of the organic 
matrix (type I collagen and non-collagenous proteins) by the protease cathepsin K. 
Osteoclasts play an essential role in bone remodeling and renewal. This process involves of 
bone matrix at several sites, followed by its replacement with new bone by osteoblasts. 
The osteoclast is a large (up to 100 µm in diameter) and highly polarized cell that occupies a 
shallow concavity called Howship’s lacuna or the subosteoclastic compartments. 
The cytoplasm of the osteoclasts is very rich in mitochondria and acidified vescicles. The 
membrane of the acidified vesicles contains H+-ATPase; mitochondria are the source of ATP to 
drive the H+-ATPase pumps required for the acidification of subosteoclastic compartments for 
the subsequent activation of the enzyme cathepsin K. Cathepsin K breaks down the bone 
organic matrix following removal of the mineral components of the bone. 
The cell domain facing the lacuna has deep infoldings of the cell membrane, the ruffled border. 
When the cell is not activate, the ruffled border disappears and the osteoclast enters into a 
resting phase. Around the circumference of the ruffled border, at the point where the cells 
membrane is closely applied to the bone just at the margins of the lacuna, actin filaments 
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accumulate and participate, together with αvβ3 integrins, to form a sealing zone. The sealing 
zone seals off the bone resorption lacuna. 
Osteoclasts are transiently active in response to a metabolic demand for the mobilization of Ca 
from bone into bone blood. Osteoclasts activity is directly regulated calcitonin, vitamin D3, and 
regulatory molecules produced by osteoblasts and stromal cells of the bone marrow. 
 
 
 
 
Figure 5: Osteoclasts in bone lacunae, coloured scanning electron micrograph (SEM). 
Magnification: x2700 when printed at 10 centimetres wide. (Images from CNRI/SCIENCE PHOTO 
LIBRARY). 
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2.3 Bone extracellular matrix 
Bone extracellular matrix consists of two basic components: organic fibers of collagen and 
inorganic mineral crystals (Figure 2). Together, they constitute about 95% of bone dry, the 
remainder is composed byother organic molecules (generally referred to as non-collagenous 
proteins) and by poorly crystalline or amorphous inorganic salts. This combination of highly 
ordered collagen fibers in association with sub-microscopic inorganic crystals gives bone unique 
biomechanical properties. Collagen is the most abundant protein in the human body and it is 
present in numerous connective tissues both calcified and not calcified. Collagen represents 
about 70-90% of non-mineralized bone matrix and its organization varies from a network of 
random bundles to a highly organized system of sheets of parallel fibers or bundles of helices. 
Collagen consists of ordered tropocollagen molecules of about 300 nm in length and 1.5 nm 
wide. The bone contains mostly type I collagen (90%) with the presence of small amounts of 
collagen type V. The fibrils are stabilized by intra and inter molecular bonds and have a 
diameter ranging between 40-120 nm, with an average of 100 nm. In type I collagen fibrils are 
wrapped in bundles to form fibers ranging in diameter from 0.2 to 12 µm. (Hing KA 2004) 
Inorganic matrix is generically referred to as HA[Ca10(PO4)6(OH)2], a plate-like crystal 20-80 nm 
in length and 2-5 nm thick. Because it is four times smaller than naturally occurring apatites and 
less perfect in structure, it is more reactive and soluble and facilitates chemical turnover. 
(Weiner S 1992) In other words, a more “perfect” crystal would be difficult to resorb, and thus 
repair of the matrix would hindered. The inorganic compound also contains further crystalline 
substance: octacalcium phosphate [Ca8H2(PO4)6.3H2O], carbon apatite [(NaCa)10(PO4CO3)6(OH)2] 
and brushite (Ca PHO4.2H2O). 
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2.4 Osteogenesis  
There are two different types of bone formation or osteogenesis, intramembranous and 
endochondral ossification (Figure 6). Both require a solid base and a well-developed vascular 
supply for the elaboration and mineralization of the extracellular matrix.  
Intramembranous ossification occurs during the embryonic development of many flat bones of 
the skull (‘membrane bones’) and jaw. During the initial stages of the process there is a 
proliferation and aggregation of mesenchymal cells, and simultaneously in the area one finds 
the development of many small blood vessels. The long processes of the mesenchymal cells are 
in contact with those of neighbouring mesenchymal cells. The mesenchymal cells begin to 
synthesize and secrete fine collagen fibrils and an amorphous gel-like substance into the 
intercellular spaces. (Wurtz T 1998) This is followed by the differentiation of the mesenchyme 
cells into osteoblasts. The osteoblasts synthesize and secrete the components of the osteoid 
which, at a later stage, becomes calcified resulting in the development of bone spicules or 
trabeculae.  
Endochondral ossification is best illustrated in the developing long bones and it is summarized 
as follows. 
1. The first stages involve the development of a hyaline cartilage model with surrounding 
perichondrium. A layer of woven bone (the periosteal collar) develops around the central shaft 
of the cartilage as a result of intramembranous ossification. 
2. Primary (diaphyseal) center of ossification. The chondrocytes in the developing central 
shaft (primary center of ossification) hypertrophy (enlarge with swollen cytoplasm) and their 
lacunae also become enlarged. The intercellular matrix becomes calcified. As a result, there is 
no diffusion through the matrix and the chondrocytes degenerate and die, leaving a network of 
calcified cartilage. At the same time, blood vessels and mesenchyme-like cells from the 
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periosteum penetrate this region of the diaphysis. Osteoblasts differentiate and begin forming 
primary bone tissue on the calcified cartilage framework. 
3. A bone marrow cavity forms in the developing diaphysis as a result of osteoclastic 
activity eroding the primary spongy bone trabeculae. The bone cavity enlarges accompanied by 
further vascularization. The further elongation of long bones occurs in the growth plates of the 
metaphysis.  
Examination of the growth plates reveals an orderly columnar arrangement of chondrocytes 
involved in the process of endochondral ossification. Several zones can be identified according 
to the arrangement and appearance of the chondrocytes: 
• resting zone (small flattened lacunae); 
• zone of proliferation (site of mitoses, and larger elliptical lacunae); 
• zone of hypertrophy (greatly enlarged and rounded chrondrocytes in enlarged lacunae); 
• zone of calcification of the matrix and degeneration of the chondrocytes; 
• zone of ossification. Osteoblasts are involved in forming bone trabeculae on the remains 
of the calcified cartilage; 
• primary spongy bone where the newly-formed trabeculae are continuously being 
eroded by osteoclastic activity and remodelled.  
During bone elongation there is a continuous addition of new cartilage cells and subsequent 
endochondral ossification, accompanied by the enlargement of the diaphyseal bone marrow 
cavity and erosion of the primary spongy bone.  
4. Secondary (epiphyseal) center of ossification. At a later stage of development blood 
vessels penetrate the epiphyses accompanied by hypertrophy of the more central cartilage cells 
and calcification of the matrix and degeneration of the chondrocytes. Osteoblasts start building 
trabecular bone on the skeleton of the calcified cartilage. The trabeculae are radially arranged.  
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5. Closure of the epiphyses. At ages 14-17, the bone cavities of the diaphysis and epiphyses 
unite, with the loss of the growth plates. This closure of the epiphyses prevents the further 
elongation of the long bones.  
Bone growth involves the coordination of a variety of cellular activities in specific sites whose 
onset and rates vary among bones and even within a single bone during its development. These 
activities are under the influence of a variety of humoral and local factors whose relative 
concentrations, sites, and sequences of appearance vary during development. 
 
 
a b  
 
Figure 6: Hematossilin & Eosin staining.a) Intramembranous ossification.Magnification 20x; b) 
Endochondral ossification.Magnification 1.25x. (Image from School of Anatomy and Human 
Biology-The University of Western Australia.http://www.lab.anhb.uwa.edu.au). 
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2.5 Modelling and Remodelling  
The ability of bone to adapt to mechanical loads is brought about by continuous bone 
resorption and bone formation. (Guldberg RE 1997) If these processes occur at different 
locations, the bone morphology is altered. Frost et al defined this as modeling. (Frost HM 1990) 
In a homeostatic equilibrium resorption and formation are balanced. In that case old bone is 
continuously replaced by new tissue. This ensures that the mechanical integrity of the bone is 
maintained but it causes no global changes in morphology. Frost et al defined this as 
remodeling (Figure7). (Frost HM 1990) 
The modeling and remodeling processes are not very different at the cellularlevel. They are 
based on the separate actions of bone resorbing cells called osteoclasts and bone forming cells 
called osteoblasts. The remodeling process begins at a quiescent bone surface with the 
appearance of osteoclasts.(Vaananen HK1995) They attach to the bone tissue matrix and form 
a ruffled border at the bone/osteoclast interface that is completely surrounded by a “sealing” 
zone. Thus the osteoclast creates an isolated microenvironment. Subsequently the osteoclast 
acidifies the microenvironment and dissolves the organic and inorganic matrices of the 
bone.(Vaananen HK 2000) Briefly after this resorptive process stops, osteoblasts appear at the 
same surface site. The osteoblasts derive from mesenchymal stem cells found in the bone 
marrow, periosteum and soft tissues. They deposit osteoid and mineralize it, so actually 
forming new bone. Some of the osteoblasts are encapsulated in the osteoid matrix and 
differentiate to osteocytes. Remaining osteoblasts continue to synthesize bone until they 
eventually stop and transform to quiescent lining cells that completely cover the newly formed 
bone surface. These lining cells are highly interconnected with the osteocytes in the bone 
matrix through a network of canaliculi. (Lian J 2001) It appears that osteoclasts and osteoblasts 
closely collaborate in the remodeling process in what is called a “Basic Multicellular 
Unit”(BMU). This indicates that a coupling mechanism must exist between formation and 
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resorption. The nature of this coupling mechanism, however, is not known. The organization of 
the BMU’s in cortical and trabecular bone differs, but these differences are mainly 
morphological rather than biological. In cortical bone the BMU forms a cylindrical canal of 
about 2000 µm long and 150-200 µm wide. It gradually burrows through the bone with a speed 
of 20-40 µm/day. In the tip, on the order of ten osteoclasts dig a circular tunnel (cutting cone) 
in the dominant loading direction. (Petrtyl M 1996) They are followed by several thousands of 
osteoblasts that fill the tunnel (closing cone) to produce a (secondary) osteon of renewed bone. 
(Parfitt AM 1994) In this way, between 2% and 5% of cortical bone is remodeled each year. The 
remodeling process in trabecular bone is mainly a surface event. Due to the much larger 
surface to volume ratio, it is more actively remodeled than cortical bone, with remodeling rates 
that can be up to 10 times higher. (Lee CA 2001) Again osteoclasts come first in the process. 
They travel across the trabecular surface with a speed of approximately 25 µm/day, digging a 
trench rather than a tunnel, with a depth of 40-60 µm. Like in cortical bone they are followed 
by osteoblast bone formation. Active remodeling sites cover areas of varying sizes from as small 
as 50×20 µm up to 1000×1000 µm. (Mosekilde L 1990) The trabecular BMU can be regarded as 
half a cortical BMU. The resulting structure that is formed is called a trabecular osteon or hemi-
osteon. (Frost HM 1986, Eriksen EF 1992)  
The cellular activities of osteoclasts and osteoblasts in modeling are basically similar to those in 
remodeling. However, in this case formation and resorption are not balanced, which causes 
changes in the micro-architecture. It can even occur that the activities of osteoclasts and 
osteoblasts are entirely uncoupled. Indeed, complete unloading may cause resorption not to be 
followed by formation. (Mosekilde L 1990) That bone formation is not necessarily preceded by 
resorption can be concluded from the observation that lining cells at the bone surface can 
transform back to bone forming osteoblasts. (Dobnig H 1995, Chow JW 1998) 
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Figure 7: The 4 Phases of Bone Remodeling. (Image from Medical illustration 2009 Nucleus 
Medical Art;http://www.sga-syndrom.de/Workshop/2010/Abstracts/Literatur/TOP3-
Knochen/Bone/Bone-083.htm). 
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3. BIOMATERIALS AND BONE 
3.1 Introduction 
A biomaterial can be defined as a substance or a combination of substances (of both synthetic 
and natural origin), employed for the treatment, improvement, augmentation, or substitution 
of tissue, organs, or function of the body. (Heini PF 2001) 
Currently used biomaterials can be divided into two categories: biological and synthetic. 
Biological materials contain in their structure signal sequences that promote cell adhesion and 
its functions. This property is due to the fact that these substances are already present in the 
human body. In particular, these substances are the elements that form the ECM, which 
together with the cells, give rise to biological tissues (i.e. collagen, hyaluronic acid….). The 
synthetic materials are usually classified in metals, ceramics, polymers and composites and 
nowadays are spreadly used in many human districts. 
Bone and joint degenerative and inflammatory disease affect millions of people worldwide. In 
fact, they account for half of all chronic diseases in people over 50 years of age in developed 
countries. In addition, it is predicted that the percentage of persons over 50 years of age 
affected by bone diseases will double by 2020. (Bone and Joint Decade's Musculoskeletal Portal 
2007) These diseases often require surgery, including total joint replacement in cases of 
deterioration of the natural joint. Besides, numerous bone fractures, low back pain, 
osteoporosis, scoliosis and other musculoskeletal problems need to be solved by using 
permanent, temporary or biodegradable devices. Therefore, orthopaedic biomaterials are 
meant to be implanted in the human body as constituents of devices that are designed to 
perform certain biological functions by substituting or repairing different tissues such as bone, 
cartilage or ligaments and tendons, and even by guiding bone repair when necessary. During 
most of the twentieth century, the availability of materials for the elaboration of implants was 
the same as for other industrial applications. Indeed, pioneer surgeons designed their implants 
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using materials available and with a successful record of industrial use such as in chemistry, 
energy, mechanical and aerospace. Since the human body consists of a highly corrosive 
environment, very stringent requirements are imposed on the candidate materials' properties. 
The basic characteristics of biomaterials are biocompatibility, biofunctionality and bioactivity. 
3.1.1 Biocompatibility, biofunctionality and bioactivity  
Biocompatibility is the essential requisite for the employment of a material in the biomedical 
field, is strictly related to the specific application and location of the biomedical device. 
The biocompatibility refers to the "property of a material to act with an appropriate response 
to the host in a specific application". (Consensus Conference of the European Society of 
Biomaterials, 2005, Sorrento, Napoli) Biocompatibility is a function not only of the 
characteristics and properties of materials (topographic and chemical properties such as 
roughness, energy, and surface charge, chemical stability, properties of the degradation 
products, etc..) and implanted devices (size, shape, stiffness, etc. .), but also of the conditions of 
the host (tissue type, implant location, age, sex, general health, drug therapies, lifestyles, etc..) 
and of the surgical technique. 
There are two main characteristics that should be considered in the evaluation of the 
biocompatibility of a material: 
 - Every implanted material "causes" a reaction in the body 
 - At the same time, "undergoes" the attack by the body 
 In fact, no material is completely inert in the biological environment. The body's responses 
depend on the nature, on the characteristics,on the site of the implanted material, and on the 
physiological state of the recipient. The biocompatibility of a material should not be 
understoodonly in reference to its biological safety, but is also related to the chemical-physical 
and mechanical properties of the material and must be controlled throughout the entire 
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production cycle, from the phase of design to that of sterilization and from the supplyingof the 
material to the final presentation of the product. 
The biofunctionality refers "to the properties that a device must have to reproduce a specific 
physical and mechanical function ". (Consensus Conference of the European Society of 
Biomaterials, 2005, Sorrento, Napoli). 
 The bioactivity is a "phenomenon by which a biomaterial stimulates or modulates a biological 
response and creates an interaction between the biomaterial and the living system through the 
activation of a specific physiological process."(Consensus Conference of the European Society 
of Biomaterials, 2005, Sorrento, Napoli). 
 
3.2 Osseointegration 
One of the main goals in orthopaedics, as well as dental and maxillofacial surgery and a pre-
requisite for clinical success is to achieve good and fast bone implant osseointegration. 
(LeGeros RZ 1993) It is of great clinical importance, as it would provide early fixation with long-
term implant stability, and it would minimize the risk of aseptic loosening; a serious 
complication in reconstructive surgery and joint replacement, thus reducing patient morbidity 
and health care cost. 
The initial observations of osseointegration were made in the 1950s by Branemark to describe 
the direct histological bone-implant contact and stated that the successful outcome of implant 
placement depends on direct structural and functional contact between living bone and the 
surface of a load-carrying implant. Since Branemark initial observations, osseointegration has 
been intensively studied and the research is ongoing. Currently, an implant is considered as 
osseointegrated when there is no progressive relative movement between the implant and the 
bone with which it has direct histological contact (Figure 8). (Borsari V 2007, Fini M 2004) 
Essentially, the process of osseointegration reflects an anchorage mechanism whereby non-
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vital components can be reliably incorporated into living bone and which persist under all 
normal conditions of loading. 
Also osteoiduction and osteoconduction of materials are essential for osseointegration.  
Osteoinductivity is the ability to induce bone formation by attracting and stimulating bone-
forming cells to the recipient while osteoconductivity is the capacity to guide bone forming 
tissue into a defect. 
 
 
 
 
Figure 8: Histological image of a titanium implant in cortical bone. The orange line represents 
the length of the newly formed bone in direct contact with the implant.Fast Green staining. 
Magnification 4x.(Histological images from Laboratory of Preclinic and Surgical Studies and 
from Laboratory of Biocompatibility, Technological Innovations and Advanced Therapies, Rizzoli 
Research Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy). 
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3.2.1 Biology of osseointegration 
Bone healing around implants involves the activation of a sequence of osteogenetic, vascular 
and immunological events that are similar to those occurring during bone healing (Figure 
9).(Franchi M 2005, Soballe K 1993) Various cell types, growth factors and cytokines are 
involved and interact throughout the stages of osseointegration, including inflammation, 
vascularisation and bone formation and ultimately bone remodelling. 
The primary host response after implantation is an inflammatory reaction elicited by the 
surgical trauma and modified by the presence of the implant. Initially, a hematoma is formed at 
the bone-implant interface and may play a role as a scaffold for peri-implant bone healing. The 
host response consists of platelet activation, migration and activation of inflammatory cells, 
vascularization, mesenchymal cells and osteoblast adhesion, proliferation, protein synthesis, 
and local factor composition. (Dimitriou R 2007) Osteoblasts attach on the implant surface from 
day one of implant insertion. Furthermore, the deposition from osteogenic cells on the implant 
surface of a layer of non-collagenous proteins that regulate cell adhesion and binding of 
minerals has been described during the early stages of host response. (Dimitriou R 2007) A few 
days after implantation, osteoblasts begin to deposit collagen matrix either in direct contact 
with the implant surface or directly on the early afibrillar interfacial zone comparable to cement 
lines, which is rich in non-collagenous proteins such as osteopontin and bone sialoprotein. 
(Puleo DA 1999) The early deposition of new calcified matrix is followed by woven bone 
formation to ensure tissue anchorage and ultimately is substituted by lamellar bone, thus 
completing the biological fixation of the implant. Peri-implant osteogenesis progresses either 
from the host bone towards the implant surface (distance osteogenesis) or from the implant 
towards to the healing bone (Dimitriou R 2007). Vascularization is essential during 
osseointegration, as it influences tissue differentiation and ossification. (FranchiM 2005) Bone 
remodelling ultimately occurs for reshaping or consolidationof bone at the implant site, 
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providing a mechanism for self-repair and adaptation to stress. Overall, osseointegration of 
implants in humans is a slow process and can take up to several months. (Dimitriou R 
2007)However, a better understanding of the cascade of events that occur at the cellular and 
molecular level at the bone implant interface is needed, in order to optimise osseointegration 
of implants. 
 
 
 
Figure 9: Various cell types, growth factors and cytokines that involve and interact throughout 
the stages of osseointegration, including inflammation, vascularisation and bone formation and 
bone remodeling at 1, 7, 15 and 90 days after the bone implant. (From: Franchi M, Fini M, 
Giavaresi G, Ottani V. Peri-implant osteogenesis in health and osteoporosis. Micron 
2005;36:630-44). 
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3.3   Pre-clinical evaluation of bone implant biomaterials 
A preclinical study is generally defined as a study conducted in vivo, i.e. in non-human animal 
models, in order to assess the efficacy and safety therapies. These studies are indispensable 
and precede clinical trials in humans. (www.genethon.fr) 
Nowadays, it is recognized that the capacity of a biomaterial to perform in patients in a specific 
function cannot be evaluated only by in vitro or in vivo evaluations, and in addition that in vitro 
testing unfortunately does not exclude in vivo testing; only by adopting both in vitro and in vivo 
methods can the limits of each single approach be reduced and the benefits increased. A 
research project that adopts only an in vitro or an in vivo method can in fact be considered to 
present some limits. Secondly, even though a study conducted only in vitro is acceptable as a 
first step, it becomes ethically unacceptable if performed only in vivo with no preliminary in 
vitro information on the biomaterial biocompatibility. The International Standard Organization 
also requires both in vitro and in vivo tests for a complete assessment of biocompatibility, 
bearing in mind the limits and benefits of each method. 
The limits of both in vitro and in vivo methods derive from the complexity of the skeletal tissue 
that presents peculiar characteristics which can only partially be reproduced experimentally: 
1. bone  is a heterogeneous tissue with different kinds of tissues and cells;  
2. bone is subjected to and influenced by mechanical forces; 
3. bone remodels during the entire life; 
4. bone is affected by many systemic and local factors, including diseases, age and the 
drugs usually taken by patients to treat various different pathologies. 
Among the factors which are increasingly improving the reliability of in vitro and in vivo testing 
for the preclinical evaluation of biomaterials are the continuous improvement in knowledge on 
bone biology acquired from basic research, the new biotechnologies for the adjustment of in 
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vitro systems, the awareness that animal suffering should be reduced as much as possible, the 
knowledge of the comparative science between humans and animals, the use of pathological 
models and, finally, the amount and accuracy of in vivo post-explantation findings. 
3.2.1 In vitro cell cultures 
In vitro cell cultures are increasingly employed to study bone-biomaterial interactions and 
provide morphological, biochemical and molecular information regarding biomaterial 
biocompatibility and matrix synthesis at the bone-biomaterial interface.  
Cell morphology, adhesion, viability, proliferation, differentiation and synthetic activity are 
usually assessed to test the effect of biomaterials on cells. (Lavos-Valereto IC 2001) The main 
advantages of in vitro tests are the ease of working, the low cost, the large number of 
experiments that can be conducted on a wide range of biomaterials in a short time andthe 
possibility of avoiding animal use and suffering, and of using human cells and tissues. The use of 
tissues from the prospective target organism greatly improves the transferability of in vitro test 
results. In vitro test sensitivity in discriminating between safe and toxic biomaterials can be of 
great importance to reject inappropriate materials prior to the in vivo implantation studies. 
(Belanger MC 2001) On the other hand, the sensitivity of in vitro biological tests is sometimes 
reported to be too low to distinguish the effects of subtle changes in substratum surface 
chemistry. (Anselme K 2000)  
It is widely recognized that in vitro tests may be limited on account of their relative simplicity 
compared to the complex interactions occurring in an organism in toto because of the lack of 
systemic and local factors due to the complexity of cell and tissue response. (Belanger MC 
2001) The impossibility of obtaining information on biomaterial and prosthetic device 
biofunctionality under physiological loads, as well as on chronic and long-term biomaterial 
effects, may bring about important limits. 
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Interspecies differences are reported to be one of the main limits to animal experimentation. 
However, researchers should take into consideration that a sort of ‘interspecies difference’ also 
affects the in vitro research results or, at least, impedes direct comparison. Osteosarcoma and 
immortalized cell lines are used, as well as primary cells from several species and anatomical 
locations. If human-derived primary cells are employed, they usually come from the surgical 
residues obtained during surgery (i.e. bone fragments unusable for tissue banking). Human 
osteosarcoma cell lines offer a number of advantages, including the absence of individual 
variability observed when primary lines are used, as well as better repeatability and 
reproducibility. However, due to their malignant origin, the findings obtained with these cell 
line models should also be evaluated with great caution. Primary osteoblasts directly cultured 
from small fragments of human and animal bone avoid mutated proliferation and marker 
expression of immortalized cell lines. Differences in the behavior of primary osteoblastic cells 
and in their expression of specific markers have been found between the various different 
species, as well as between the various different immortalized cells lines currently used. 
(Torricelli P 2003) 
3.2.2 In vivo animal models 
Animal models provide important knowledge on biomaterials that can eventually lead to the 
development of more effective clinical treatments of diseases in both humans and animals, 
thus acting as a bridge between in vitro studies and clinical trials. 
Depending on the purpose of the study, biomaterials are usually implanted in the diaphyseal 
(cortical bone and medullar cavity), metaphyseal or epiphyseal part of long bones (cancellous 
bone). The commonest tests on bone implants are radiographic, histologic, histomorphometric 
and biomechanical investigations which may follow in vitro tests. They provide a complete 
characterization of the osteogenetic and osteointegration properties of the material, showing 
its potential as bone implant for orthopedic surgery. (Fini M 2003) The inflammatory response 
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to the implant and the osteoinductive properties can also be examined thanks to the 
implantation in animal soft tissues. 
The benefits of in vivo tests may of course be the limits of in vitro tests: to give an example, the 
possibility of performing chronic and long-term investigations and studying the biofunctionality 
and effectiveness of the final prosthetic device manufactured with the biomaterial under 
investigation. These evaluations, moreover, are performed in the biological environment. In 
vivo experimentation requires a great deal of legal authorizations, and as such differs from the 
in vitro activity. The in vivo study must be performed by strictly following Italian and European 
Law on animal experimentation: Law by Decree January 27, 1992, No. 116.  Every country has 
its own regulations but a regional local ethical committee usually exists and every research 
protocol is also to be sent to and approved by the responsible public authorities. Only qualified 
personnel are authorized to use animals and in vivo laboratories should be certified in order to 
guarantee animal welfare.  
The majority of bone implants are studied in vivo under unloaded conditions, also following the 
regulations by the International Standard Organization to study mainly implant material and 
bone-implant interface isolated from the effects of cyclic weight bearing. However, if a material 
appears to be promising in this application, it may then be tested under the influence of 
loading. 
In vivo it has been demonstrated that load application on stable implants changes tissue 
response and material reabsorption in relation to the surface characteristics of the implants. 
The in vivo implant site is also of great importance from a mechanical point of view. Forces 
acting on the implants placed in the tibial or femoral diaphysis are mainly shear forces, and 
have a negative effect on the final bone behavior. In contrast, the total force acting on the 
implants in the tibial and femoral condyles is a combination of sheer and compression forces 
which have a beneficial effect on the remodelling process at the bone-implant interface. 
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(Vercaigne S 1998)  The implant site also greatly affects both osseointegration and the rate of 
biodegradationof the some biomaterials. Osseointegration is usually higher in cortical bone 
which is followed by trabecular bone and medullar, respectively. Regarding the biodegradation 
it is frequently higher in medullar that is followed by trabecular bone and cortical bone, 
respectively. 
An almost insurmountable limit of in vivo studies is the presence of differences between 
humans and animals so that data on bone remodelling and formation obtained from animals 
may not be representative of bone healing in humans. 
Finally to overcome the differences between humans and animals is fundamental to 
understand that: “an appropriated use of animal models for studies on biomaterials in tissue-
engineered research begins with careful considerations of the question asked…a lot of 
questions can be asked and the answer is not always simple to give in one animal model”. 
(Einhorn TA 1999) 
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4. CALCIUM PHOSPHATE CERAMICS AND BONE 
One of the most promising groups of synthetic bone substitutes are calcium phosphate 
ceramics (CaPs). The most commonly used CaPs are HAand tricalcium phosphate (TCP) or an 
intrinsic combination of the two (LeGeros RZ 2002, LeGeros RZ 2003). The rationale for the 
development of CaPs has been their similarity in composition to bone mineral and their 
similarities in some properties of bone, such as biodegradability, bioactivity and 
osteoconductivity. Another important property of bone, interconnecting porosity can be 
introduced during the manufacturing process of CaPs. Moreover, CaPs are known to have 
relatively low mechanical properties.(LeGeros RZ 2008) Proper understanding of these 
properties, both biological and mechanical, are critical for the successful application of CaPs as 
bone substitutes.  
 
4.1 Calcium phosphate ceramics as bone substitute 
CaPs ceramics have been the most widely investigated and used in orthopedic surgery. TCP and 
HA can be structured with pores that range from 100 to 200 μm in diameter. Their porosity 
enables mesenchymal cell migration, adhesion, proliferation and differentiation into 
osteoblasts within their pores. This unique structure constitutes their osteoconductive 
characteristics. 
HA and TCP ceramics are both brittle materials with low fracture resistance. They can be varied 
in chemical and structural composition. Different preparative methods lead to either a compact 
or porous material with interconnective macropores that are the spatial and structural 
equivalent of cancellous bone. In a biologic system, more crystallization and higher material 
density result in greater mechanical strength and resistance to dissolution, and promote long-
lasting stability. In contrast, an amorphous ultra-structure and greater porosity enhance 
interface activity and bone ingrowth, as well as early biodegradation of the material. 
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Commercially available HA is resorbed very slowly, if at all, under normal physiologic 
conditions, whereas TCP generally is resorbed within 6 weeks after implantation. When used as 
a mixture, biodegradable HA/ TCP graft material has the ability to dissolve, break down and 
allow new bone formation and remodeling required to attain optimal mechanical strength 
without interference. A fully non-resorbable graft material may hinder remodeling, prolong the 
strength deficiency of new bone and leave permanent stress risers in the fusion mass.  
 
4.2 Bone cell–ceramic interactions  
Although TCP and HA derived through thermal treatment do not exist naturally, they have been 
shown to induce a biological response similar to that of bone. (LeGeros RZ 2002, LeGeros RZ 
2008) Cells attach to and engulf the CaPs, causing them to biodegrade in vitro and in vivo. CaPs 
allow osteoblast cells to attach, proliferate, and differentiate. Differentiating osteoblast cells 
produce collagen type I, alkaline phosphatase, proteoglycans, and matrix proteins, such as 
osteocalcin, osteopontin, and bone sialoprotein known to signify bone formation. (LeGeros RZ 
2008) Cellular response is affected by the composition of CaPs. Factors that affect cellular 
response to CaPs include surface topography (roughness), geometry, composition, and particle 
size. (LeGeros RZ 2008) 
 
4.3 Biodegradability 
Ideally, the rate of resorption of CaPs is similar to the rate of new bone formation but for 
obvious reasons not any faster. In vivo biodegradability can be achieved by dissolution or is cell 
mediated. The population of cells responsible for the resorption of CaPs mainly consists of 
multinuclear cells and osteoclasts. However, macrophages are involved in the phagocytosis of 
CaPs as well. (Gisep A 2003) The speed of biodegradability and the cell type involved in the 
resorption process are determined by both material properties, such as Ca/P ratio, crystallinity, 
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particle size, surface area, and porosity and the local biological environment, such as pH, the 
presence of cells, and H2O content.(LeGeros RZ 2002) In general, CaPs consisting of TCP have 
higher degradation rates as compared to CaPs consisting of HA.(Hing KA 2004) Recently, new 
tools have been developed to assess the incorporation, remodelling, and resorption of 
biomaterials in patients. High-resolution peripheral QCT makes it possible to assess changes in 
bone and biomaterial/CaP structure and density in vivo/in situ with a relatively high resolution. 
(Mueller TL 2011) The low radiation exposure associated with this technique makes longitudinal 
follow-up in patients possible and will provide long-term clinical data of the incorporation, 
remodelling and resorption bone substitute materials over time.  
 
4.4 Porosity 
Many studies have demonstrated a greater degree and faster rate of bone ingrowth or 
apposition with percentage porosity; however, there still seems to be some dispute regarding 
the optimum ‘‘type’’ of porosity. The rate and quality of bone integration have been related to 
a dependence on pore size, porosity volume fraction, and interconnectivity, both as a function 
of structural permeability and mechanics. (Hing KA 2005) Bone regeneration in a scaffold in vivo 
involves recruitment and penetration of cells from the surrounding bone tissue, as well as 
vascularization. Higher porosity is expected to enhance osteogenesis and numerous studies 
have verified this hypothesis. These results were likely due to the larger surface area that 
resulted in higher ion exchange and bone-inducing factor adsorption.(Hing KA 2005) There are a 
limited number of reports in the literature that show no effect of porosity on the amount of 
apposited bone.(Fisher JP 2002, Kujala S2003) The absence of any reports on the beneficial 
effects of lower porosity scaffolds in vivo solidifies the requirement of highly porous implants 
for bone regeneration. Microporosity results in larger surface area that is believed to contribute 
to higher bone inducing protein adsorption as well as to ion exchange and bone-like apatite 
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formation by dissolution and re-precipitation. (Hing KA 2005) Surface roughness enhances 
attachment, proliferation and differentiation of anchorage dependent bone forming cells. High 
porosity and large pores enhance bone ingrowth and osseointegration of the implant after 
surgery. (Karageorgiou V2005)  Other factors, such as the rate of degradation and the 
mechanical performance of the scaffold should be taken into account when porosity is 
assessed. 
 
4.5 Pore size 
Pores in calcium phosphate materials are necessary for bone tissue formation because they 
allow migration and proliferation of osteoblasts and mesenchymal cells, as well as 
vascularization. In addition, a porous surface improves mechanical interlocking (interdigitation) 
between the implant biomaterial and the surrounding natural bone, providing greater 
mechanical stability at this critical interface. (Karageorgiou V 2005) Pore size can be divided in 
two different groups: microporous (<5 µm pores) and macroporous (>100 µm pores). 
(Karageorgiou V 2005, Blokhuis TJ 2000) Microporosity and macroporosity are important for 
the bioresorbability of the material. In addition, macroporosity plays an important role in the 
osteoconductivity. (LeGeros RZ 2002, 2008) The minimum recommended pore size for a bone 
substitute is 100 µm, but subsequent studies have shown better osteogenesis for substitutes 
with pores >300 mm. (Hulbert SF 1970, Karageorgiou V 2005, Kuboki Y 2002)  Smaller pores 
(75– 100 µm) resulted in ingrowth of unmineralized osteoid tissue or were penetrated only by 
fibrous tissue (10–44 and 44–75 µm). (Hulbert SF 1970). A very interesting aspect of the effect 
of pore size on bone regeneration is the impact on the progression towards osteogenesis. 
Relatively larger pores favors direct osteogenesis, since they allow vascularization and high 
oxygenation, whilst smaller pores result in osteochondral ossification, although the type of 
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bone ingrowth depends on the material itself and the geometry of the pores. (Kuboki Y 2002, 
Jin QM 2000) 
 
4.6 Interconnectivity 
Another important factor that determines the effectiveness of porosity is the structure of the 
pores with respect to each other. The pores may either be interconnecting or they contain 
‘‘deadends’’. (Blokhuis TJ 2000) Interconnecting macroporosity is introduced by adding 
porogens, such as naphthalene, H2O2, polymeric porogens or using the foaming 
method.(LeGeros RZ 2003) Microporosity depends on sintering temperature or sintering 
program. CaPs sintered at 1200 °C shows significantly less microporosity than that sintered at 
1000 °C and a dramatic change in crystal size. (LeGeros RZ 2003)  In general, CaPs with 
interconnective pores are advantageous over biomaterials containing dead-end pores, because 
a spatial continuous connection of the pore system has a decisive meaning for the ingrowth of 
new bone, especially in long-term tissue interface maintenance. (Blokhuis TJ 2000) However, 
when used in combination with osteogenic cells, materials containing interconnective pores are 
less able to contain osteogenic cells, resulting in a longer period until the pore space has been 
filled with newly formed bone.(Dennis JE 1992) 
 
4.7 Biomechanical properties 
The property that is most often used to characterize the mechanical behaviour of bone 
substitutes is their compressive strength. Since these materials are intended to be used as bone 
substitutes, it is important to keep in mind that the compressive strength of human cortical 
bone ranges between 90 and 230 MPa (with tensile strengths ranging from 90 to 190 MPa), 
whereas the compressive strength of cancellous bone ranges between 2 and 45 MPa. (Ginebra 
MP 2008, An YH 2000) CaPs generally provide limited biomechanical support, because they are 
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brittle and have little tensile strength. TCPs are less brittle compared with HA. However, the 
faster degradation of TCP results in subsequent quicker loss of mechanical strength over time. 
Although increased porosity and pore size facilitate bone ingrowth, the result is a reduction in 
mechanical properties, since this compromises the structural integrity of the scaffold. 
Moreover, scaffolds fabricated from ceramics with a high degradation rate should not have 
high porosities (>90%), since rapid depletion of the material will compromise the mechanical 
and structural integrity before substitution by newly formed bone. (Karageorgiou V 2005) 
However, there is an upper limit in porosity and pore size set by constraints associated with 
mechanical properties. An increase in the void volume results in a reduction in mechanical 
strength of the scaffold, which can be critical for regeneration in load-bearing bones. For 
example, an increase of the total porous volume from 10 to 20% results in a factor four 
decrease in mechanical strength. (Lane JM 1998, Blokhuis TJ 2000) The extent to which pore 
size can be increased whilst maintaining mechanical requirements is dependent on many 
factors, including the nature of the material and the processing conditions used in its 
fabrication. 
 
4.8 Osteoinductivity 
In contrast to the limited number of reports on osteoinduction by polymers and metals, 
ceramics – particularly calcium phosphate based ones – have shown osteoinductive potential in 
a variety of studies: HA, β-TCP, biphasic calcium phosphate (BCP), that designates the mixture 
of HA and TCP, dicalcium phosphate anhydrous (DCPA), dicalcium phosphate dihydrate (DCPD), 
carbonated apatite, calcium pyrophosphates (CPP) and HA/calcium carbonate (CC) mixtures 
(Figure 10). (Barradas AM 2011)Chemical composition, overall geometry of the implant, 
porosity, microstructural surface properties, including grain size, microporosity, surface 
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roughness and specific surface area have been suggested as critical factors in osteoinduction. 
(Yamasaki H and Sakai H 1992, Yuan H 1999, Habibovic P 2005, Yuan H 2010) 
 The osteoinductive properties of CaPs materials appear to be based on their architectural 
features, such as surface geometry, topography, poresize, and porosity which allow entrapment 
and concentration of circulating bone mineral proteins (BMPs) in the biologic fluid. (Reddi AH 
2000) The main challenge remains to determine the appropriate architecture for these 
materials to optimize the ability to entrap and concentrate growth factors and/or 
osteoprogenitor cells. Independent of architectural features, CaPs or CaP-based composite 
materials combined with BMPs, osteoprogenitor cells, and bioactive proteins or peptides have 
been shown to enhance bone formation. (Seeherman H 2005, Arinzeh TL 2005) The main 
challenges for this so-called engineered osteoinductivity are to determine the optimal scaffold, 
the appropriate dose of osteogenic factors, and the controlled release of these factors for 
different applications. 
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Figure 9: Schematic diagram presenting materials that have been described as osteoinductive, 
divided according to material family, origin and physico-chemical and structural properties. 
Poly-HEMA: poly-hydroxyethylmethacrylate; Ti: titanium; PP: pyrophosphate; HA: 
hydroxyapatite; CC: calcium carbonate; BCP: biphasic calcium phosphate; TCP: tricalcium 
phosphate; DCPD: dicalcium phosphate dihydrate; DCPA: dicalcium phosphate anhydrous; CA: 
carbonated apatite; OCP: octacalcium phosphate. (From: Barradas AM et al, Eur Cell Mater. 
2011 May 15;21:407-29) 
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5. OSTEOPOROSIS AND BIOMATERIALS 
5.1 Osteoporosis 
The currently accepted definition of osteoporosis is ‘a systemic skeletal disease characterized 
by a reduction in bone mass and micro-architectural deterioration of bone tissue, with a 
consequent increase in bone fragility and susceptibility to fracture risk (Figure 10). (Consensus 
Development Conference, 1993) Osteoporosis is a major global problem, because over 10 
million people are currently diagnosed with osteoporosis. (Sung Bae Park 2011) Although 80% 
of osteoporotic patients are women, a considerable number of men are also affected. (Sung 
Bae P 2011) The age matched prevalence of osteoporosis is 17-20% of women over 50 years 
old, 26% over 65 years old and 50% over 85 years old in the United States.  
 
a    b  
Figure 10:  Trabecular bone. a) healthy; b)osteoporotic:reduction in bone mass and micro-
architectural deterioration of bone tissue. Hematossilin & Eosin staining. Magnification 20x. 
((Histological images from Laboratory of Preclinic and Surgical Studies and from Laboratory of 
Biocompatibility, Technological Innovations and Advanced Therapies, Rizzoli Research 
Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy). 
 
Osteoporosis behaves as a silent disease. A high percentage of the affected people are not 
aware they have the condition. Therefore, the burden of osteoporosis is the burden of its 
clinical outcome: osteoporotic fractures, which are generally recognised as low-trauma fracture 
resulting from low bone mineral density (BMD). The best characterised are, by order of the 
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related disability burden, hip fracture, vertebral fracture and wrist fracture. There are other 
peripheral fractures related to low density or poor quality of bone mass such as proximal 
humeral, pelvic, rib, proximal tibia or ankle fractures (Figure 11). 
Osteoporosis may be either a primary or a secondary form. Primary osteoporosis is the more 
common form and is due to the typical age-related loss of bone from skeleton. It is classified as 
type-1 and type-2. Type-1, or postmenopausal osteoporosis, affects women within 15 to 20 
years of menopause. Women manifest two phases of type-1 age-related bone loss. The first, at 
menopause, is caused by estrogen deficiency and results in an uneven increase in bone 
resorption, as compared with formation, that mainly affects trabecular bone. This is called 
‘high-turnover’ osteoporosis. After 4-8 years, ‘low-turnover’ osteoporosis begins, with a slower 
and constant loss of both trabecular and cortical bone, primarily caused by decreased bone 
formation. (Tilg H 2008) 
Estrogen deficiency is thought to underlie type-1 osteoporosis, rendering the skeleton more 
sensitive to parathyroid hormone (PTH), resulting in increased calcium (Ca) resorption from 
bone. This in turn decreases PTH secretion, 1,25-dihydroxyvitamin D production and Ca 
absorption. This ultimately causes loss of trabecular bone, leading to vertebral crush fractures 
and femoral neck and distal forearm fractures. Quantitative measurements of the amount of 
bone resorption in post-menopausal women is equal to 425 mg/day of Ca, while bone 
formation is only 387mg/day; this results in a net daily loss of 38 mg of Ca. (Consensus 
Development Conference, 1993) 
Type-2, or senile osteoporosis, occurs in women or men more than 70 years of age.  Type-2 
osteoporosis is generally referred to as a low-turnover osteoporosis and it is usually associated 
with decreased bone formation along with decreased ability of the kidney to produce 1,25-
dihydroxyvitamin D. This vitamin D deficiency results in decreased Ca absorption, secondary 
hyperparathyroidism, and increased bone resorption. Cortical and trabecular bone is lost and 
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this leads to increased risk of hip, long bone, and vertebral compression fractures. (World 
Health Organization 1994)  
Men exhibit only the slow phase of bone loss, most likely due to decreased levels of bio-
available testosterone and estrogen associated with increased levels of sex-hormone binding 
globulin (SHBG). Decreased estrogen causes an increased bone resorption, while decreased 
testosterone is responsible for decreased bone formation. 
Secondary osteoporosis results from the presence of other diseases or altered conditions that 
predispose to bone loss and is classified as type-3.  This form of osteoporosis occurs equally in 
men and women and at any age. Secondary osteoporosis is associated with a variety of 
conditions, including endocrine imbalances (as Cushing’s syndrome, hypo- and hyper-
thyroidism, and hypogonadism), cancer (notably multiple myeloma), gastrointestinal disorders 
(especially celiac and inflammatory bowel diseases due to malabsorption), drug use (such as 
corticosteroids, cancer chemotherapy, anticonvulsants, heparin, barbiturates, benzodiazepines, 
valporic acid, gonadotropin-releasing hormone, and excessive use of aluminium-containing 
antacids), genetic disorders (cystic fibrosis and osteogenesi imperfecta), rheumatic and 
autoimmune diseases (lupus and rheumatoid arthritis), chronic kidney disease and other 
specific conditions (alcoholism, cigarette smoking, depression, immobilization, obesity, and 
poor nutrition, including malnutrition due to eating disorders). (Torricelli P 2008, Fini M 2011) 
Among the parameters that can be measured today, BMD is the most used predictor of 
osteoporotic fractures. The World Health Organization (WHO) has defined osteoporosis as the 
state of having a BMD greater than 2.5 standard deviation (SD) below peak adult bone mass, 
whether or not a fragility fracture has occurred, based on epidemiological studies on the risk of 
osteoporotic fractures. (Cummings SR 1985, 1989)  Osteopenia is defined as a BMD between 1 
and 2.5 SD below that of a young normal adult. Using standardized bone density measurements 
of the total hip, “normal” bone is greater than 833 mg/cm2, “osteopenia” is between 833 and 
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648 mg/cm2, and “osteoporosis” is lower than 648 mg/cm2. In order to distinguish the 
asymptomatic condition of having low bone mass without fractures, the WHO has suggested 
that the term “severe osteoporosis” has to be reserved for patients with a fragility fracture. The 
current emphasis on BMD in the diagnosis and treatment of osteoporosis limits awareness of 
the importance of bone quality. It has been shown that loss of connectivity within the network 
of trabecular bone is also a fracture risk factor independent of BMD. (Legrand E 2000) 
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Figure 11: (A) Fragility fractures typically involve wrist, vertebrae, and hip. (B) Microcomputed 
tomography shows marked trabecular thinning of osteoporotic bone compared with normal 
bone.(Microcomputed tomography images from Laboratory of Preclinical and Surgical Studies 
and from Laboratory of Biocompatibility, Technological Innovations and Advanced Therapies, 
Rizzoli Research Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy) (C) 
Microscopic views of bone-resorbing osteoclasts and bone-forming osteoblasts: (1) osteoclast 
with its distinctive morphology; (2) tartrate-resistant acidic phosphatase staining of 
multinucleated osteoclasts; (3) multiple osteoblasts (white arrowheads) on mineralised matrix; 
(4) alkaline phosphatase staining of osteoblasts. (From Tilman D Rachner et al. Lancet 2011; 
377: 1276–87) 
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5.2 Bone remodelling and osteoporosis 
Osteoporosis has been classically defined in a pathogenic manner as an uncoupling in which 
resorption exceeds formation resulting in a net loss of bone (Figure 12). Bone remodelling is a 
continuous physiological process that occurs in adult skeleton in which bone resorption is 
followed by new bone formation, maintaining mechanical strength and structure.  
 
 
 
Figure 12: Representation of the bone remodeling cycle in osteoporosis. (Image from Dr. 
Gideon A. Rodan, Research Vice President, Merck Research Laboratories, Merck & Co., Inc., 
West Point, Pennsylvania). 
 
Most conditions that lead to osteoporosis, including estrogen deficiency, hyperparathyroidism 
and hyperthyroidism are associated with osteoclastic bone resorption. 
Basic multicellular units (BMUs) compose the remodelling unit of bone and include: osteoclasts 
which stimulate bone resorption, osteoblasts, which are responsible for new bone formation, 
and osteocytes, older osteoblasts surrounded by bone and present in a reduced state of 
activity. The bone remodelling cycle begins with activation of resting osteoblasts on the surface 
of bone and marrow stromal cells. This is followed by a cascade of signals originating from the 
activated osteoblasts, to osteoclasts and their precursors. These intercellular signals recruit and 
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differentiate multinucleated cells from hematopoietic stem cells. After osteoclast-induced bone 
resorption, matrix components such as Transforming Growth Factor-β (TGF-β) and Insulin-like 
growth factor I (IGF-I), as well as collagen, osteocalcin and other protein and mineral 
components, are released into the micro environment. Growth factors released by resorption 
contribute to the recruitment of new osteoblasts to the bone surface, which begin the process 
of collagen synthesis and mineralization. In healthy adults as many as two million remodelling 
sites may be active at any given time, and it is estimated that nearly one fourth of all trabecular 
bone is remodelled each year. In general resorption takes only 10-13 days, while formation is 
much more deliberate and can take upwards of three months. (Eriksen 1996) 
There are several control points of the remodelling cycle which are susceptible to systemic and 
local alterations and when perturbed, can lead to deleterious changes in bone mass. 
Remodelling begins following estrogen deprivation, or in response to endogenous PTH 
hormone fluxes, cytokine stimulation, growth hormone surges, glucocorticoid excess or 
changes in serum calcium. For the most part, estrogen deprivation remains one of the most 
common and critical elements in shifting resorption rates to a higher set point. In estrogen 
deficiency, hyperparathyroidism, and hyperthyroidism-associated bone loss, there is clear 
histological and biochemical evidence for increased bone resorption and increased osteoclastic 
recruitment. (Tilman D Rachner 2011) 
External signals (such as PTH, growth hormone, interleukin-1, estrogen deprivation) to resting 
osteoblasts and stromal cells cause these cells to release an number of cytokines (i.e. 
interleukins (IL) such as IL-1, -6, -11 as well as Tumor Necrosis Factor α (TNF-α) and TGF-β) 
which enhance the recruitment and differentiative function of multinucleated giant cells 
destined to become bone resorbing cells. Studies in mice have demonstrated the obligatory 
requirement of receptor-activating NF-kB (RANK) ligand (RANKL), a TNF-related cytochine, and 
its receptor RANK for osteoclast formation and activity. (Tilman DR 2011) RANK-ligand activity is 
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tightly modulated by its soluble neutralizing receptor osteoprotogerin (OPG), a soluble peptide 
originally described as a factor which markedly inhibited bone resorption and osteoclast 
differentiation in vitro. (Bucay 1998) Agents that stimulate bone resorption in vivo and increase 
osteoclast formation from bone marrow cultures in vitro were shown to modulate 
RANK/RANKL/OPG production and signal transduction in cultures. (Rodan GA 2002) Many of 
these agents have previously been implicated in the pathogenesis of oteoporosis, including 
PTH, prostaglandin E, IL-1, TNFα and IL-6. (Rodan GA 2002)In fact, estrogens can affect the 
production of local factors, including cytochines, prostaglandins and growth factors. Estrogen 
deficiency increases the activity of IL-1 and TNF-α, IL-6, as well as prostaglandins. (Manolagas 
SC 1995) Estrogen can increase TGF-β, leading to oateoclast apoptosis and increases OPG which 
would block both formation and activity of osteoclasts. (Hofbauer LC 1999) 
The next step in the remodelling cycle to be considered in the pathophysiology of osteoporosis 
is bone formation. The osteoblast functions not only to signal osteoclasts during remodelling, 
but also to lay down collagen and orchestrate mineralization of previously resorbed lacunae in 
the skeletal matrix. These complex functions are tied to differentiation of mesenchymal stem 
cells which become osteoblasts and rest on the surface of the remodelling space. Recruitment 
of stem cells to osteoblasts, rather than adipocytes is a critical step in bone formation and 
requires a series of factors that enhance differentiation. One of the most important 
components of this process is Cbfa1, a transcription factor which is essential in the early 
differentiative pathway of stem cells to bone and away from adipocytes.  
With activation of resting osteoblasts, these cells synthesize several types of collagen as well as 
elaborating a series of growth factors such as IGF-I, IGF-II, TGF-β. These, in turn, are necessary 
for further recruitment of bone forming cells. In addition, osteoblasts deposit growth factors in 
the skeletal matrix where they are stored in latent forms, and released during subsequent 
remodelling cycles.  
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Glucocorticoid induced osteoporosis also results from an uncoupled remodelling unit: 
pharmacologic doses of glucocorticoids suppress bone formation through its actions on IGF-I 
and other growth factors; in addition, glucocorticoids enhance osteoblastic apoptosis; 
glucocorticoids enhance the release of cytokines and other factors such as RANK ligand, that 
stimulate bone resorption; glucocorticoids reduce production of 1,25 dihydroxyvitamin D3 
thereby lowering Ca absorption from the gut and raising PTH secretion; high doses of 
glucocorticoids often suppress gonadotropin secretion thereby reducing production of sex 
steroids. 
 
5.3 Osteoporotic fractures 
The definition of an osteoporotic fracture is not straightforward. (Kanis JA 2005,Engelke K 2006, 
Glüer CC 2006) A widely adopted approach is to consider fractures from low energy trauma as 
being osteoporotic. Low energy may variously be defined as a fall from a standing height, or 
trauma that in a healthy individual would not give rise to fracture. This characterization of low 
trauma indicates that the vast majority of hip and forearm fractures are low energy injuries. At 
the age of 50 years, approximately 75% of people hospitalized for vertebral fractures have 
fractures that are attributable to low energy injuries, increasing to 100% by the age of 90 years. 
The rising incidence of fractures with age does not provide direct evidence for osteoporosis, 
since a rising incidence of falls could also be a cause. By contrast, a lack of increasing incidence 
of fractures with age is reasonable presumptive evidence that a fracture is unlikely to be 
osteoporosis related.  
In women, fracture incidence begins to increase around the age of fifty (time of menopause), 
and in men the increase begins later, in about the mid-sixties. These fractures in the older age 
groups are typically the result of minimal trauma and occur at the hip, spine, and wrist with 
incidence of them higher in women than in men.  
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The most common form of osteoporotic fractures is vertebral compression fractures; each year 
in the United States, an estimated 500,000 to 700,000 women suffer their first vertebral 
fracture.(Burge R 2007, Melton LJ III 1993)With a growing aging population, the direct cost 
associated with osteoporosis-related injuries is estimated to exceed $60 billion in 2030. 
(Wasnich RD 1996) 
Vertebral compression fractures put patients with osteoporosis at much greater risk for 
developing local (at the level of the fracture) and global (across several vertebral levels, eg, 
scoliosis) changes in spine structure, kyphotic deformities (eg, dowager’s hump), and spinal 
stenosis secondary to sagittal imbalance and degenerative changes. (Keller TS 2003, Heini PF 
2007)Vertebral fracture may result in pain around the fracture site, loss of height caused by 
vertebral collapse, spinal instability, and, in many cases, kyphotic deformity.(Silverman SL 1992) 
These complications often result in mild to severe pain and limitation of mobility, and thus 
reduce functional activities of daily living. The quality of life is influenced by pain and 
progressive loss of activity. (Chen LH 2011)In general, it is difficult for spine surgeons to treat 
patients with osteoporosis surgically because advanced age and other comorbidities associated 
with osteoporosis make them poor candidates for surgery and the associated risks of 
anesthesia. (Heini PF 2007,Kim WJ 2006,Ponnusamy KE 2011)In such patients, nonsurgical and 
medical treatments can help relieve symptoms and help prevent the development and 
progression of spinal deformities. Surgical intervention with instrumentation for the 
osteoporotic spine is sometimes a clinical necessity, but it is difficult because of the inherent 
risks of construct failure in poor bone stock. Novel approaches and instruments have been 
designed to increase purchase and reduce implant subsidence and the incidence of revision 
surgery as a result of construct failure in this patient population. The success of these 
techniques depends on integrating biomaterial, biologic, and biomechanical aspects with 
clinical considerations. 
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5.4 Osteoporosis complication treatment 
When osteosynthesis devices or cementless implants are inserted in bone for fracture fixation, 
joint replacement and prosthetic dentistry, mechanisms underlying the osseointegration 
process involve a cascade of various cellular and extracellular events. (Augat P 2005) The role of 
osteoporosis in the success of bone implants needs further investigations, however 
microarchitectural deterioration and biological drawbacks affecting cells of both osteoblastic 
and osteoclastic lineages, extracellular matrix proteins, local and systemic regulatory factors 
can negatively influence the early bone response and the bone remodelling processes around 
implants.  
Many in vitro and in vivo experimental researches and clinical studies demonstrated that aging 
and estrogen deficiency cause a decrease of the osteointegration rate and bone density around 
common orthopaedic implant materials. (Fini M 2001 and 2004, Torricelli P 2000, 2002 and 
2003, Alsaadi G 2007, Borsari V 2007) It is supposed that even the ideal clinically used 
biomaterial could fail if implanted in a compromised microenvironment. As an example, human 
Demineralized Bone Matrix (DBM) that is the gold standard of osteoinductive biomaterials, 
decrease the osteoinductive potential when implanted in female rats with low estrogen levels. 
(McMillan J 2007)  
Therefore, new solutions acting on biomaterials are required to stimulate bone formation and 
osteofixation of implants and many strategies have been proposed to decrease failure risks of 
implantation surgery in patients affected by osteoporosis and needing reconstructive therapies 
because of fragility fractures, degenerative diseases or edentulism. These strategies could be 
divided into 2 main groups:  
- strategies directly focused on modifying biomaterial features as design, surface 
chemistry and bioactivity, roughness and topography; 
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- strategies focused on local and systemic substances/therapies delivered by biomaterials 
which can be used as adjuvants to stimulate endogenous tissue healing. 
Implant design may maximize the bone-implant interface, while chemical and topographical 
properties of the implant surface can be critical for protein adsorption which mediates cell 
adhesion, can recruit bone forming cells and stimulate cell proliferation and extracellular matrix 
protein synthesis. Cells interact with the environment (and also with biomaterial surfaces) 
through transmembrane and intracellular receptors that mediate cell division, maturation, gene 
expression, collagen and other ECM protein synthesis. (Hing KA 2004) Regarding implant 
chemistry, the use of ceramic coatings (i.e. HA, tricalcium phosphate) on metallic materials is 
suggested to reverse the negative effects of osteoporotic conditions both in animal models and 
in patients. (Fini M 2003) Changes in cell-protein-material interface communications, 
dissolution and release of specific key ions that act on local cells to up regulate gene expression 
or influence cell differentiation have been advocated to explain the stimulatory effect of HA 
and other ceramic coatings. (Hing KA 2004) However, in some studies the use of an 
osteoconductive HA coating was not sufficient in restoring normal physiological bone ingrowth 
in estrogen deficient subjects. (Kurth AHA 2005)  
The sensitivity of bone cells is not limited to chemical phenomena but also to the surface 
topography. (Hing KA 2004) The implant surface roughness combined with proper implant 
chemistry was demonstrated to be an important “geometrical mediator” of bioactivity for bone 
cells and tissue also in the case of aged and osteoporotic bone. In the cases of insufficient bone 
quantity implants with a high roughness profile have demonstrated superior outcomes 
compared to smooth surfaces. (Le Guehennec L 2007) High roughness (Ra ~ 12-18µm) 
biomaterials with and without HA coating, behaved similarly without differences in the 
osteointegration rate in young, aged and estrogen-deficient animals. (Borsari V 2009)  
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The amount of growth factors (GF) and the number of bone cells capable of being stimulated by 
a bioactive surface decrease as a consequence of patient aging and estrogen deficiency and at 
present many researchers are working also on the combination between biomaterials and 
drugs or signalling molecules such as ions, peptides and proteins. (Marquis ME 2007)  
BPs are typical anti-resorptive agents that include AL, ibandronate, etidronate and 
pamidronate. Oral BPs have become the most widely used drugs in the treatment of 
osteoporosis; they significantly reduce the risk of new fractures in women with 
postmenopausal osteoporosis.BPs display a common backbone structure of P–C–P, where C is 
carbon and each P is a phosphonate group. The two phosphonate groups are essential both for 
binding to HA and for the biochemical mechanism of action. Individual BPs are characterized by 
the two covalently bonded side chains attached to the central carbon atom, termed R1 and R2, 
which determine the efficiency of the compound. Binding to bone is enhanced when R1 is a 
hydroxyl group, whereas the R2 side group has some effect on binding but predominantly 
determines the antiresorptive potency of the BPs. In particular, the R2 side chain of nitrogen-
containing BPs, N-BPs, can also influence overall bone affinity as a result of the ability of the 
nitrogen moiety to interact with the crystal surface of bone mineral. (Chesnut III C 2004,Coxon 
FP 2006) The presence of nitrogen groups within the R2 side group is associated with the ability 
of an individual BP to inhibit farnesyl pyrophosphate (FPP) synthase, a major enzyme in the 
mevalonate pathway (Figure 13). As a result, many of the activities of the osteoclasts are 
disrupted, including migration, attachment, and resorption, and ultimately, cell death can occur 
via apoptosis (Figure 14). (Russell RGG 2007)Recently, an increasing body of literature has 
suggested that BPs use, especially intravenous preparations, may be associated with 
osteonecrosis of the jaws. Thus, some experts caution that the benefits of prolonged use of BPs 
must be carefully weighed against the potential negative effects of over suppression of bone 
metabolism.(Ott SM 2005) On this basis, the development of strategies for local administration 
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of BPs becomes even more interesting. Recently, BPs have been used locally applied or 
immobilized on the surface of implants or by systemically administered in osteoporotic animals 
and patients submitted to implantation surgery. (Stadelmann VA 2008)   
 
 
 
Figure 13: A new classification of BPs based on mechanism of action. Non-nitrogen containing 
BPs (N-BPs) acts by incorporation into ATP whereas alkyl-amino BPs acts by interfering with 
farnesyl pyrophosphate synthase (FPPS). The heterocyclic N-BPs also inhibits the FPPS enzyme 
and in addition stabilize conformational changes that magnify their inhibitory potency.(Image 
from: R. Graham G. Russell, BPs. An Update on Mechanisms of Action and How These Relate to 
Clinical Efficacy, Ann. N.Y. Acad. Sci. 1117: 209–257; 2007) 
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Figure 14:This is a hypothetical scheme to illustrate how BPs may distribute within bone, 
depending on differences in their mineral affinity. It is proposed that BPs with differing affinities 
for bone mineral will gain access to different degrees to the various skeletal compartments, 
such as trabecular and cortical bone or endosteal and periosteal sites. At a microanatomical 
level distribution to sites of formation and resorption and within the canalicular network of the 
osteocyte mechanical sensing system may also depend on the mineral affinity and inherent 
charge of individual BPs. This will then influence their actions on osteoclasts and osteocytes. 
FPPS: farnesyl pyrophosphate synthase; GTPase: guanine triphosphate; ERKs: extracellular 
signal-regulated kinases (Image from R. Graham G. Russell, BPs. An Update on Mechanisms of 
Action and How These Relate to Clinical Efficacy,Ann. N.Y. Acad. Sci. 1117: 209–257; 2007) 
 
Also Sr, that is an inorganic ion and a natural component of food and beverages, has the ability 
to enhance bone volume and prevent bone loss; thereby Sr has become increasingly attractive 
for the prevention and treatment of osteoporosis. There are in vitro and in vivo studies that 
elucidate the ability of Sr treatment to promote osteoblast-related gene expression and 
alkaline phosphatase of osteogenic-differentiating mesenchymal stem cells and, when 
coadministered with calcium in ovariectomized goats, to increase new bone matrix formation in 
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a dose-dependent manner. Thus, the growing evidence of the beneficial effect of Sr on bone 
justifies the increasing interest toward Sr incorporation in biomaterials, as Ca phosphate 
bioceramics and cements. (Landi E 2007) 
Combination of biomaterials with growth factors, mesenchymal stem cells, and different forms 
of biophysical stimulation, hormones and other signalling molecules demonstrated to have a 
beneficial effect on the process of osteointegration due to the ability to induce osteoblast 
development, bone regeneration and vascularization. (Dallari D 2009) 
During the last years also new strategies are growing thanks to the development of 
biotechnology. Biomimetic coating methods are inspired by the natural process of 
biomineralization. The deposition of calcium phosphates apatite crystals onto metallic surfaces 
with different techniques (electrodeposition, immersion in SBF or in supersaturated CaP 
solution) forms a biomimetic coating of biological apatite which serves as biomimetic matrix for 
osteogenic cell attachment and growth. Biomimetic innovative biomaterials were successfully 
tested in vitro and in vivo healthy preclinical models but no data are available on the efficacy of 
these materials in osteoporotic bone of pathological animal models. (Le Guehennec L 2007) 
Future trends of innovative research investigate on nanomaterials that matching natural bone 
have been proposed as the next generation of orthopaedic implant materials with the aim to 
improve surface properties of the implant by possessing a greater surface area, to create an 
environment more conducive and to promote osteoblast function. (Tasker LH 2007) Cells of our 
body are predisposed to interact with nanostructured surfaces, because all living systems are 
governed and are composed by molecular building blocks at nanometer scales, as proteins, 
nucleic acids, lipids and carbohydrates. (Christenson EM 2007) Nanobiomaterials, possessing 
higher surface area to volume ratio than conventional microscale biomaterials, have 
demonstrated to provide advantageous interactions with the protein that control cellular 
function, in particular fibronectin, vitronectin, laminin and collagen. (Webster TJ 2001) 
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Although nanobiomaterials seem to be an attractive strategy, no data are available when 
implanted in compromised osteoporotic bone in preclinical studies. 
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6. AIM OF THE STUDY 
The bone regeneration, both the physiological one that, during the entire life of humans, is 
coupled with the bone remodeling and the reparative one that follows every bone injury, 
represents a great problem in orthopedic surgery.  
Recent advance in synthetic biomaterials research give to use the possibility to investigate new 
solution in the field of bone substitute. Synthetic biomaterials, due to their non-biological 
origin, have no cross contamination risk; but there is the stringent need to study their 
biocompatibility and clinical outcome. 
The aims of this thesis were to investigate the in vitro and in vivo behavior of:   
1) to manufacture a biomimetic gelatin- calcium phosphate bone cement and to carry out the 
preclinical biological studies on healthy bone defects; 
2) to develop an AL-HA nanocomposite material prepared using different concentrations of AL 
and a Sr-HA nanocrystal prepared from solutions containing different concentrations of Sr atom 
and to carry out preclinical biological studies on healthy and osteoporotic bone. 
Preclinical biological studies were aimed to evaluate: 
-biocompatibility in vitro and in vivo (following Organization of Standardization (ISO) guides 
10993); 
-effects on bone cells behavior; 
-preclinical effectiveness in bone defects and in healing of bone in osteoporosis. 
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7. BIOMIMETIC GELATIN- CALCIUM PHOSPHATE BONE CEMENT 
7.1 Introduction 
Since they were first proposed in early 1980s, calcium phosphate bone cements (CPs) attracted 
increasing interest because of their very good biocompatibility and bioactivity (Brown WE 
1986). Furthermore, CPs bone cements can be molded into the desired shape during 
implantation, and they easily adapt to bone cavities and defects with a consequent close 
apposition to the host tissue. (Fernandez E 1999) 
Since the first proposed formulation, a variety of CPs based on different compositions have 
been proposed, and the influence of a number of parameters, such as composition of the liquid 
phase, powder to liquid ratio, Ca/P molar ratio, presence of additives on the setting properties 
of the cements have been investigated. Bigi et al. have previously studied the effect of gelatin 
on the setting properties of an α-tricalcium phosphate, α-Ca3(PO4)2 (α-TCP), based cement. 
(Bigi A 2004 and 2004,Gbureck U 2003, Fernandez E 1999, Durucan C 2000, Sarda S 2002 ) This 
approach follows a biomimetic strategy, because of the properties of the composite cement. α-
TCP, one of the main components of several bioactive calcium phosphate cements, is by far 
more soluble than HA, and it hydrolyses in aqueous solution through a mechanism, which 
implies dissolution and successive precipitation of a more stable phase. (Bigi A 2002)At 
physiological values of pH and temperature, the product of hydrolysis is calcium deficient HA 
(CDHA). On the other hand, gelatin can be obtained by degradation of collagen, the main 
proteic component of bone tissue, and it is widely employed in the biomedical field, for wound 
dressing, three dimensional tissue regeneration, preparation of capsules and microspheres. 
Thus, the setting reaction of the gelatin enriched cement leads to the formation of a composite 
material where both the organic and the inorganic phases resemble those of bone. Bigi et al. 
have shown that the onset of the setting reaction of α-TCP is promoted by the presence of a 
small amount of brushite, CaHPO4.2H2O (DCPD), and that the rate of conversion into CDHA is 
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accelerated by the presence of gelatin. (Bigi A 2004) The presence of gelatin induces a 
reduction of the crystallinity and of the mean dimensions of the CDHA crystals, leading to a 
more compact microstructure, which can account for the improved mechanical properties of 
the cement. The remarkable improvement of the setting properties of the calcium phosphate 
cement due to the presence of gelatin suggest that the biomimetic composite material could be 
successfully applied as calcium phosphate cement.  
On this basis aim of this thesis was to study the in vitro and in vivoresponse onto the composite 
gelatin-cement (GEL-CP) and compared the results with those simultaneously obtained on the 
cement with the same calcium phosphate composition prepared in the absence of gelatin (C-
CP) and on HA. For this purpose we have carried out an in vitro study on osteoblast cultures 
grown on GEL-CP, C-CP and HA and an in vivo study, in healthy rabbits, in order to examinate 
the bone healing rete and osteointegration  of these materials. 
 
7.2 Materials and methods 
7.2.1 Tested materials: structural and mechanical characterization 
α-TCP was performed in theDepartment of Chemistry, “G. Ciamician”, Bologna University by 
solid state reaction of a mixture of CaCO3 and CaHPO4·2H2O in the molar ratio of 1:2 at 1300°C 
for 5 hours. (Bigi A 2002) Type A gelatin from pig skin (Italgelatin S.p.A.) was used. α-TCP 
powder was added to gelatin aqueous solutions in the appropriate amount in order to obtain 
15% wt of gelatin in the composite material, allowed to dry at room temperature, and then 
accurately mixed with 5% wt of DCPD (CaHPO4.2H2O, Merck). At variance, control cement 
contained just α-TCP (95% wt) and DCPD (5% wt) without gelatin. The liquid phase (distilled 
water) and the cement powders were mixed in a mortar for 60 s to obtain a paste of workable 
consistency, using a liquid/powder ratio of 0.3 ml/g. Teflon moulds were used to prepare 
cement cylinders (6 mm in diameter and 12 mm high for structural and mechanical 
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characterization, 12 mm in diameter and 12 mm high for cell culture), which were immersed in 
simulated body fluid (SBF) at 37°C for 7 days. 
For the structural and mechanical characterization initial and final setting times were 
determined by the Gillmore method (ASTM: C 266-89. Standard test method for time of setting 
of hydraulic cement paste by Gillmore needles). After this the cements were demoulded and 
immediately submitted to compression tests by using a 4465 Instron testing machine, equipped 
with a 1KN load cell. At least six specimens for each composition were tested at a crosshead 
speed of 1 mm/min. For X-ray diffraction investigation, the samples were demoulded and 
immediately immersed in liquid nitrogen for 10 min, in order to stop the setting reaction, and 
then ground in a mortar. The samples were packed into recessed silicon slides. X-ray diffraction 
analysis was carried out by means of a Philips PW 1050/81-powder diffractometer equipped 
with a graphite monochromator in the diffracted beam. CuKα radiation was used (40 mA, 40 
kV). Morphological investigation of the fractured surfaces of the cement samples was 
performed using a Philips XL-20 Scanning Electron Microscope. The samples were 
sputtercoated with gold prior to examination. 
7.2.2 In vitro study 
Human osteoblast-like cell line MG63 was used for the in vitro tests. Osteoblasts were 
cultivated in DMEM (10% FCS, 100 IU/mL penicillin and 100 μg/mL streptomycin solution), and 
incubated at 37°C in a humidified 95% air / 5% CO2 atmosphere. Cells were released before 
confluence with 0.05% (w/v) trypsin and 0.02% (w/v) EDTA, counted (Coulter Counter Z1, 
Beckman Coulter Inc., Miami, FL, USA) and were used at a concentration of 2 × 104 cells/mL for 
the experiment. 
Six samples of calcium phosphate cement prepared in the absence of gelatin (C-CP) and 
composite gelatin-cement (GEL-CP), previouslysubmitted to gamma ray sterilization, were 
placed in each of four 24-well plates and a cell suspension (2.0 × 104 cells/mL) of MG63 was 
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directly seeded on every sample. The same amount of cells was plated in polystyrene wells of 
each plate without materials as Control (C). Plates were incubated in standard conditions, 
changing medium every two days. DMEM additioned with ß-glycerophosphate (10-8M) and 
ascorbic acid (50μg/mL) was used to activate osteoblasts for osteocalcin production. At the end 
of experimental times (3, 7, 14 and 21 days) the supernatant was collected from the wells and 
centrifuged to remove particulates, if any. Aliquots were dispensed in Eppendorf tubes for 
storage at -80°C and following quantitative test. 
Cell proliferation and viability. At 3, 7, 14 and 21 days the Cell Proliferation Reagent WST-1 
(Roche Diagnostic GmbH Mannheim, Germany) test was done to assess cell proliferation and 
viability.  The assay is based on the enzymatic cleavage of the tetrazolium salt WST-1 to 
formazan by cellular mitochondrial dehydrogenases present in viable cells.  Briefly 100 μL of 
WST1 solution and 900 μL of medium (final dilution: 1:10) were added to the cell monolayer, 
and the multi-well plates were incubated at 37°C for a further 4 h. Supernatants were 
quantified spectrophotometrically at 450 nm with a reference wavelength of 640 nm. Results 
are reported as optical density (OD). 
Type I Collagen (CICP). CICP is the primary organic constituent of bone. The determination of 
type I collagen production was based on the amount of C-terminal type I procollagen (CICP) 
present in the cell supernatant and measured using a specific enzyme-linked immunoassay 
(Prolagen-C enzyme Immunoassay kit, Metra Biosystem, CA, USA).  
Transforming Growth Factor ß1(TGF-ß1). TGF-ß1 is ubiquitously expressed during embryonic 
development and in most adult tissues, regulating proliferation, differentiation, and apoptosis. 
In the bone tissue, TGF-ß1 is reported to influence cell proliferation, stimulate extracellular 
matrix production. TGF-ß1 was measured using the assay quantikine human TGF-ß1 
(Immunoassay, R&D Systems, MN, USA) in cell culture supernatant by employing a quantitative 
sandwich enzyme immunoassay technique. 
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Interleukin-6(IL-6). IL-6 is an interleukin that acts as both a pro-inflammatory and anti-
inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune 
response, e.g. during infection and after trauma, especially burns or other tissue damage 
leading to inflammation. Particularly, is considered a marker of the low tolerance of a 
biomaterial both in vitro and in vivo. IL-6 was measured using the assay human IL-
6Immunoassay kit (Biosource International, CA, USA) in cell culture supernatant by employing a 
quantitative sandwich enzyme immunoassay technique. 
Alkaline Phosphatase activity(ALP). ALP is a member of a family of zinc metalloprotein enzymes 
that function to split off a terminal phosphate group from an organic phosphate ester. ALP 
immunoassays (ALP, Sigma Kinetic Method Kit, St. Louis, MO, USA) were tested on 
supernatants immediately after collection. The measured concentrations were normalized by 
cell number. 
Osteocalcin (OC). OC is a noncollagenous protein found in bone and dentin. Osteocalcin is 
secreted solely by osteoblasts and thought to play a role in the body's metabolic regulation and 
is pro-osteoblastic, or bone-building, by nature. The OC quantitative determination was 
assessed by the OC immunoassay (Novocalcin Enzyme Immunoassay Kit, Metra Biosystem, CA, 
USA) on collected supernatants immediately after collection. The measured concentrations 
were normalized by cell number. 
Cell morphology. Samples for each material, at the end of experimental times, were processed 
for Scanning Electron Micrographs (SEM): osteoblasts grown on the materials were fixed in 
2.5% glutaraldehyde, in pH 7.4 phosphate buffer 0.01 m for 1 h and dehydrated in a graded 
ethanol series. After a passage in hexamethyldisilazane, the samples were air dried. The 
samples were sputter-coated with gold prior to examination with a Philips XL-20 Scanning 
Electron Microscope. 
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7.2.3 Microhardness 
Samples of C-CP and GEL-CP, new and after 21 days in cell culture medium, were included in 
polymethylmethacrilate and were used to measure bone hardness by means of an indentation 
test (Microhardness VMHT 30, Leica, Wien, Austria). Briefly, a rotatory wheelset at 150 rpm 
was used with SiC paper and water lubrification. The resin-embedded blocks containing the 
specimen were then polished using a diamond paste with progressively finer grain size. The 
smooth surface obtained was observed using a microscope and clearly showed the material 
surface to be examined. The microhardness measurements were taken tangentially to the 
surface with a Vickers indenter (foursided pyramid with square base and an apex angle 
between opposite sides of 136°±15’) applied to the material at a load of 0.05 Kgf and dwell time 
of 5 sec (Figure 15). The Vickers hardness degree (HV) was calculated by dividing the 
indentation force by the surface of the imprint (4 pyramidal surfaces) observed with the 
microscope. The average value for each sample was calculated on a mean of 10 for each 
examined area. 
 
 
 
Figure 15: Microhardness measurements.Pyramid with square base and an apex angle between 
opposite sides of 136°±15’. (Images from Laboratory of Preclinical and Surgical Studies and from 
Laboratory of Biocompatibility, Technological Innovations and Advanced Therapies, Rizzoli 
Research Innovation Technology, Rizzoli Orthopaedic Institute, Bologna, Italy). 
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7.2.4Statistical analyses 
Statistical evaluation of data was done using the software package SPSS/PC+ Statistics TM 10.1 
(SPSS Inc., Chicago, IL USA). The experiment was repeated three times and the results 
presented are the mean of the triplicate values. Data are reported as mean ± standard 
deviations (SD) at a significance level of p<0.05. After having verified normal distribution and 
homogeneity of variance, a one-way ANOVA was done for comparison between groups. Finally, 
the Scheffé’s post hoc multiple comparison tests were performed to detect significant 
differences between groups. 
7.2.5In vivo study 
The in vivo study was performed by strictly following Italian and European Law on animal 
experimentation: Law by Decree January 27, 1992, No. 116.  Briefly, the experimental animal 
protocol was sent and approved by the local ethical committee and by the responsible 
authorities and to the Italian Ministry of Health. Following Laws on animal experimentation 
animals were acquired from authorities farms, submitted to a quarantine period of at least ten 
days before the utilization and to a standard and controlled diet. All surgical procedures were 
performed under general anesthesia, with the control of animal welfare by a veterinarian and 
with post-operative analgesic therapy.  
Twelve skeletally mature, adult New Zealand White disease-free rabbit (Charles River, Calco, 
Lecco, Italy) of the same age and sex (weight: 2.700±0.250 Kg) were housed under controlled 
conditions (room temperature 22±0.5 °C; relative humidity 55±5%; 12 h light and 12 h 
darkness) and were supplied with standard diets and water ad libitum. At time of surgery, 
general anesthesia was induced with an intramuscular injection of 44 mg/kg ketamine (Ketavet 
100, Farmaceutici Gellini SpA, Aprilia Lt, Italy) and 3 mg/kg xylazine (Rompun Bayer AG, 
Leverkusen, Germany), and assisted ventilation (O2:1 l/min; N2O: 0.4 l/min; isofluorane: 2.5–
3%). After shaving, disinfection and sterile draping of the operation site, a 2-cm skin incision 
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was made on the lateral aspect of distal femoral condyle. Bilateral confined cancellous defects 
were drilled in both limbs per step with a 3.2-mm drill that was subsequently expanded with a 6 
mm drill. The depth of the defect was 10±0.5 mm. All the drill holes were carefully rinsed with 
Rinder’s solution and cleaned out, so that any abraded particles formed during drilling were 
removed. 
 In 4 rabbits the defects were treated with C-CP, in 4 with GEL-CP and in the last 4 with HA. Two 
animals for each group were sacrificed after 4-week while the other two were sacrificed after 
12-weeks. Antibiotic therapy (Cefazolin, 100mg/Kg) was administered preoperatively, 
immediately after surgery and after 24 hrs. Analgesics (metamizole chloride, 50mg/Kg) were 
prescribed in the immediate postoperative period.  
On days 10, 9, 2 and 1 prior to sacrifice, the rabbit received an intramuscular injection of 
oxytetracycline (30mg/kg).  
Four and 12-week after surgery, the animals were anesthetized as described above and then 
pharmacologically euthanized with intravenous injection of Tanax (Hoechst AG, Frankfurt-am-
Mein, Germany). Femurs were removed, stripped of soft tissues and, after macroscopic 
observation, were processed for histological, histomorphometrical investigations. 
Histology and histomorphometry. The femoral condylar trabecular  bone of rabbits were fixed 
in 4%  para-formaldehyde for 48 h for undecalcified bone processing; the samples were then 
dehydrated in graded series of alcohols (24 hrs respectively in each 50°, 75°, 95°) until the 
absolute was reached. After a 24 h-infiltration period in methylmetacrilate, they were finally 
embedded in poly-methylmetacrilate (Merck, Schuchardt, Hohenbrunn, Germany). Femur 
blocks were sectioned along a plane perpendicular to the bone surface using Leica 1600 
diamond saw microtome (Leica SpA, Milan, Italy).  A series of 150 ± 10 μm in thickness were 
obtained and then thinned and polished (Struers Dap-7, Struers Tech, Denmark) to a thickness 
of 30 ± 10 μm. A total of 3 sections for each implant one superficial, one in the middle and one 
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depth were analyzed by means of histological and histomorphometric studies. They were 
stained with Toluidine Blue, Acid Fucsin and Fast Green and processed for routine histological 
and histomorphometrical analyses by using a transmission and polarized light  optic Olympus 
BX41 microscope (Olympus, Melville, USA) and the QWIN image analysis software (Leica 
Imaginig System Ltd, Cambridge, England).  
In the rabbit condyles two parameters were histomorphometrically measured by two blinded 
investigators: the defect-healing rate and the bone-implant contact (BIC). The first was 
calculated as percentage of the bone area re-grown in the defect divided by the initial area of 
the defect (initial defect area = 28.60 mm²). The second consist in a percentage which is the 
length of the region where bone is in direct contact with the implant divided by the total length 
of the interface multiplied by 100. The analysis regarding defect-healing rate was developed at 
a 1.25x magnification; while the analysis of the other parameter, bone-implant contact, was 
developed at a 2.5x magnification, sharing out the images field in four quadrants. 
Dynamic histomorphometry by tetracycline labeling of the newly-formed bone at the bone 
interface gave measurement of the rate of mineral apposition (MAR) (μm/day) and the rate of 
bone formation (BFR/BS) (μm2/μm/day). The analyses were developed at 10x magnification. 
These are reported as indices of osteoblast teams and their activity following the nomenclature 
and methodology approved by the American Society of Bone and Mineral Research. 
Microcomputed tomography. Microtomography uses x-rays to create cross-sections of a 3D-
object that later can be used to recreate a virtual model without destroying the original model. 
The term micro is used to indicate that the pixel sizes of the cross-sections are in the 
micrometer range. In the field of orthopaedic research, X-ray micro-tomography has become a 
frequently used method for the investigation of bone specimens. The reason is that a µCT 
system permits the non-destructive investigation of trabecular and cortical bone specimens 
without any special preparation of the sample. 
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After dehydratation in graded series of alcohols and before the embedding in poly-methyl-
methacrilate 1 samples for each group at 12 weeks were randomly analyzed by Micro-CT 
SkyScan 1172 (µCT, SKYSCAN, Kartuizersweg 3B 2550 Kontich, Belgium). The samples were 
maintained in parafilm, to prevent drying, and they were scanned. The specimens were 
scanned with the high resolution microtomography system Skyscan 1172 at a source voltage of 
100 kV, at a source current of 100 μA and using an Al + Cu filter of 0,5mm. Each sample was 
rotated until 180 degrees with a rotation step of 0.4 degrees and a frame averaging of 4. The 
images pixel size was 15.59 μm. Each scanning dataset obtained after the cone beam 
acquisition consisted of approximately 600 images in 16-bit tiff format (2000 X 1150 pixels). The 
images obtained from acquisition were later reconstructed by the software NRecon (version 
1.4.4) without any correction but the specific post-alignment depended on acquisition. 
7.2.6 Statistical analysis  
Statistical analysis was performed using the SPSS v.21.1 software (SPSS Inc., Chicago, Illinois, 
USA). Data are reported at a significance level of p<0.05. After having verified the normal 
distribution of data, the one-way ANOVA followed by the Dunnet’s t post hoc tests was used to 
analyze histomorphometric data by considering HA as a reference material. 
 
7.3 Results 
7.3.1 Tested materials: structural and mechanical characterization 
Regarding the structural and mechanical property of our experimental material carried out by 
Department of Chemistry, “G. Ciamician”, Bologna University,  Bigi et al reported that the 
setting times of the cement was accelerated by the presence of gelatin inside the cement. (Bigi 
A 2004) However, the recorded values ensure a reasonable period of workability for the GEL-CP 
samples, as well. The powder X-ray diffraction patterns of both GEL-CP and C-CP after 7 days of 
soaking into SBF displayed just the diffraction peaks characteristic of HA, in agreement with the 
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complete conversion of α-TCP. Moreover, SEM results showed that the fractured surface of C-
CP was completely covered of entangled plate-like crystals, with the characteristic morphology 
of apatite obtained from the setting reaction of α-TCP. (Bigi A 2004) The plate-like entangled 
crystals do not fill the whole volume, and leave small voids or pores all over the cement. At 
variance, the pores were almost absent on the fractured surface of GEL-CP where it is quite 
difficult to distinguish the crystals due to their small dimensions. In agreement with previous 
data, the compressive strength is significantly greater for the sample containing gelatin (GEL-
CP) with respect to control (CCP), and assumes a mean value that is about five times that 
recorded for C-CP. 
7.3.2 In vitro study 
Osteoblasts were cultivated for 21 days on C-CP and GEL-CP samples. At 3, 7 14 and 21 days cell 
proliferation and metabolic activity were tested. Cell proliferation is shown in Figure 16. 
Starting from the same baseline condition, at 3 days proliferation of osteoblasts grown on C-CP 
was significantly lower than cells grown on GEL-CP and C (p<0.005). At 7 days osteoblasts on 
both biomaterials were significantly lower than C (p<0.001), and C-CP group was lower than 
GEL-CP (p<0.001). At 14 and 21 days there were no differences in proliferation between 
osteoblasts grown on GEL-CP and C, while cells grown on C-CP remained significantly lower 
than the other groups. Alkaline phosphatase (Figure 17a) at 3 days showed the highest values in 
C groups (p<0.0001) in comparison with C-CP and GEL-CP, and GEL-CP group values were higher 
than C-CP group (p<0.0001). At 7, 14 and 21 days ALP values in GEL-CP group were always the 
highest when compared to both C-CP and C (p<0.001). The latest showed no differences 
between them. Figure 17b shows CICP level: at 3 days C group level of CICP was higher than C-
CP group (p<0.05), while there were no differences in comparison with GEL-CP group. At 7 days 
CICP of GEL-CP group reached the highest values (p<0.05) when compared to C-CP and C group. 
At 14 days GEL-CP was higher only in comparison with C group (p<0.05) and at 21 days there 
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were no differences among all groups. Osteocalcin production (Figure17c) was not affected by 
the presence of the materials and was not statistically different from C at any time. Level of 
TGF-ß1 was not different among the three groups at 3, 7 and 14 days, while at 21 days values in 
C-CP group were significantly lower than GEL-CP and C group (p<0.01) (Figure17d). Interleukin-
6 production (Figure17e) was significantly higher in both biomaterials when compared to C 
(p<0.005) at 3 days, but in the following experimental times no more differences were found. 
 
 
Figure 16:  Osteoblast proliferation and viability after 21 days of culture on GEL-CP, C-CP, and 
polystyrene (C). Mean, n = 6 triplicates. Scheffé post hoc multiple comparison test: * p<0.005: 
C-CP versus GEL-CP and C; ** p<0.001: C versusGEL-CP and C-CP; GEL-CP versus C-CP; *** 
p<0.0001: C-CP versus GEL-CP and C. 
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Figure 17:  Cell differentiation, synthetic activity and cytokine production after 21days of 
culture on GEL-CP, C-CP, and polystyrene (C). Mean ± SD, n = 6 triplicates. Scheffé post hoc 
multiple comparison test: (a) ALP activity: *** p<0.0001: C versus GEL-CP and C-CP; GEL-CP 
versus C-CP; ** p<0.001: GEL-CP versus C-CP and C; (b) CICP production: * p<0.05. 1: C-CP 
versus C; 2: GEL-CP versus C-CP and C; 3: GEL-CP versus C; (c) OC production: ns; (d) TGF-α 
release: ** p<0.01: C-CP versus GEL-CP and C; (e) IL-6 release: ** p<0.005: C versus GEL-CP and 
C-CP. 
 
Osteoblast attachment and spreading was examined on randomly taken samples at 7, 14 and 
21 days by SEM.Cell responses were uniform across the surface of thecements. In agreement 
with proliferation data, cellattachment and spreading increase noticeably from 7 to14 days. 
With increasing time cell morphology modifiesfrom round to oval to flattened, and extensive 
cell processformation occurs. At each experimental time, the cellsgrown on GEL-CP samples 
(Figures 18b, d, f) appear moreflattened and display much more filopodia than thosegrown on 
C-CP (Figures 18a, c, e). 
 
 
e 
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Figure 18: SEM images of human osteoblasts MG63 on (a, c, e) C-CP, and (b, d, f) GEL-CP. (a, b): 
7 days of culturing; (c, d): 14 days of culturing; (e, f): 21 days of culturing. 
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7.3.3 Microhardness 
Biomaterial surfaces were tested for microhardness to verify if culture in cell culture medium 
interacted with surface or chemical composition, modifying material hardness properties. 
Results of microhardness analysis are shown in Table I. Basal microhardness of C-CP samples 
was statistically higher than Basal GEL-CP and C-CP after DMEM culture for 21 days. Values of 
GEL-CP samples after DMEM culture were significantly higher when compared to Basal GEL-CP 
and both C-CP Basal and after DMEM culture. 
 
Table I: Microhardness analysis of experimentals biomaterials. 
Cement Basal DMEM (21 days) 
C-CP 24.9 ± 1.9* 23.1 ± 1.6 
GEL-CP 22.8 ± 1.1 28.4 ± 1.9** 
 
* Basal C-CP versus DMEM C-CP, Basal GEL-CP (p<0.05); ** DMEM GEL-CP versus Basal C-CP 
and GEL-CP, DMEM C-CP (p<0.0001). 
 
7.3.4 In vivo study 
The twelve rabbit tolerated the surgical procedure well and remained in good health during the 
experimental periods. At the end of the implantation time, a total of 24 implants could be 
retrieved. Macroscopically there were no signs of inflammation or adverse tissue reaction. 
Histology and histomorphometry. The evaluation of the osseous implantation by light 
microscopy showed the biocompatible behavior of tested materials that did not evoke tissue 
inflammation, foreign body reactions or degeneration and necrosis in the surrounding bony 
tissue at the examined experimental times (Figure 19). The light microscopically evaluation 
revealed a very uniform bone reaction for all specimens within the same group at the various 
implantation times and there were no obvious signs of material degradation. Bone formation 
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started at the defect walls and had a woven bone-like appearance. Bone was deposited directly 
at the material surface without intervening fibrous tissue. Histologic sections of C-CP (Figure 
20a, 20b), GEL-CP (Figure 20c, 20d), and HA (Figure 20e, 20f), treated defects showed at 4 
weeks thin and dense trabeculae forming from the old bone and progressively head toward the 
material. These trabeculae of new formed bone were closely related with the material. In 
histological sections of HA treated defects new bone was apposed also between HA bead 
(Figure 20e, f). At 12 weeks of implantation, bone ingrowth had proceeded compared with 4-
weeks and material was slightly degraded compared with 4-week specimens. Nevertheless, a 
significant part of the material was maintained. A tight contact existed between the bone and 
material surface without the presence of an intervening fibrous layer. At 12 weeks, in the 
histologic sections of C-CP (Figure 21a, b), GEL-CP (Figure 21c, d), and HA (Figure 21e, f), the 
defect area was not healed, but the newly formed trabecular bone changed morphology and 
micro-architecture: the thin and dense trabeculae, seen at 4 weeks, were remodeled and 
appeared similar to the surrounding healthy bone. 
The fluorochrome labeled sections of the 4-weeks and 12-week specimens confirmed that 
indeed bone formation had started at the drill defect (Figure 22a-d). The sections also showed 
that active remodeling around the materials had occurred. 
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Figure 19: Histological sections from the distal femoral condyle of rabbits. Toluidine-blue, Acid 
Fucsin, Fast Green staining. Magnification 1.25x. M: material; Nb: new trabecular bone. 
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Figure 20: Histological sections from the distal femoral condyle of rabbits at 4 weeks. Toluidine-
blue, Acid Fucsin, Fast Green staining. a) Histologic section of C-CP treated defects, resolution 
1.25x.  b) Histologic section of C-CP treated defects. Magnification 4x. c) Histologic section of 
GEL-CP treated defects.Magnification 1.25x. d) Histologic section of GEL-CP treated defects. 
Magnification 4x.  e) Histologic section of HA treated defects.Magnification 1.25x. f) Histologic 
section of HA treated defects. Magnification 4x. M: material; Nb: new trabecular bone. 
 
M 
Nb 
Nb 
M 
M 
Nb 
M 
Nb 
M 
Nb 
80 
 
 
a  b  
c  d  
e  f  
 
Figure 21: Histological sections from the distal femoral condyle of rabbits at 12 weeks. 
Toluidine-blue, Acid Fucsin, Fast Green staining. a) Histologic section of C-CP treated 
defects.Magnification 1.25x.  b) Histologic section of C-CP treated defects. Magnification 4x. c) 
Histologic section of GEL-CP treated defects.Magnification 1.25x. d) Histologic section of GEL-CP 
treated defects. Magnification 4x.  c) Histologic section of HA treated defects.Magnification 
1.25x. d) Histologic section of HA treated defects. Magnification 4x. M: material; Nb: new 
trabecular bone. 
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Figure 22: Fluorochrome labels show bone formation from the surface of the 
implant.Magnification 10x. a) Histologic section of C-CP at 4 weeks; b) Histologic section of GEL-
CP at 4 weeks; c) Histologic section of C-CP at 12 weeks; d) Histologic section of GEL-CP at 12 
weeks. 
 
The histomorphometrical results for C-CP, GEL-CP, and HA, implants at 4-weeks and 12-weeks 
can be found respectively in Table II and in Table III. To evaluate the degradation of the 
implanted materials the percentage of the defects healing was quantified for each 
experimental time.   
Statistical analyses at 4-weeks (Table II) showed that HA implant had significantly higher value 
of Healing rate than in GEL-CP implant (p<0.05), but no significant differences were observed 
M 
Nb 
M 
Nb 
M 
M 
Nb 
Nb 
82 
 
between C-CP implant and HA implant and between C-CP implant and GEL-CP implant. No 
significant differences were observed along the three implants regarding the BIC. 
Dynamic histomorphometry by tetracycline labeling of the newly-formed bone at the -bone 
interface gave measurement of the MAR (μm/day) and the BFR/BS (μm2/μm/day) that were 
significantly higher (MAR:p<0.05 and BFR/BS: p<0.05), in C-CP implant in comparison to GEL-CP 
implant and HA implant. No significant differences were observed between GEL-CP implant and 
HA implant. At 12-weeks (Table III) only the healing rate showed significantly higher value in HA 
implants in comparison to C-CP implants (p<0.05) and GEL-CP implants (p<0.005). No significant 
differences were spotlight for BIC, MAR and BFR/BS.  
 
Table II: Statistical analysis of histomorphometrical measurements at 4 weeks. Data were 
expressed as Means ±  Standard Deviation. 
 C-CP GEL-CP HA 
Healing rate (%) 50 ± 6 41 ± 10* 58 ± 3 
BIC (%) 51 ± 6 50 ± 15 57 ± 7 
MAR(μm/day) 3.91 ± 0.82* 3.65 ± 0.70 2.50 ± 0.60 
BFR/BS (μm3/μm2/day) 2.53 ± 1.16* 2.03 ± 0.58 0.91 ± 0.23 
Dunnet’s t test by considering HA as Control Group: *, p<0.05; **, p<0.005 
Table III: Statistical analysis of histomorphometrical measurements at 12 weeks.Data are 
expressed as Means ±  Standard Deviation. 
 C-CP GEL-CP HA 
Healing rate (%) 67 ± 15* 57 ± 19** 98 ± 2 
BIC (%) 41 ± 12 35 ± 3 52 ± 11 
MAR(μm/day) 2.42 ± 0.21 2.40 ± 0.76 3.27 ± 0.70 
BFR/BS (μm3/μm2/day) 0.99 ± 0.11 1.46 ± 0.56 1.33 ± 0.49 
Dunnet’s t test by considering HA as Control Group: *, p<0.05; **, p<0.005 
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Microcomputed tomography.The evaluation of the osseous implantation by Microcomputed 
tomography analysis showed microtomographical images of C-CP (Figure 16a), GEL-CP (Figure 
16b), and HA (Figure 16c) 12 weeks after surgery.  According to histological evaluation all these 
images showed dense mineralized bone trabeculae growing around the defect. 
 
a           b  
 
c  
Figure 23: Micro-CT SkyScan 1172 (µCT, SKYSCAN, Kartuizersweg 3B 2550 Kontich, Belgium) 
images of a) C-CP; b) GEL-CP; c) HA, treated defects at 4 weeks. Images were acquired at 12-bit 
grey level image, 2000x1150 pixel, 15.59 µm image pixel sizes, with Aluminium + Copper filter. 
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7.5 Discussion and conclusions 
Previous studies carried out on the cement materials by Department of Chemistry, “G. 
Ciamician”, Bologna University, showed that the presence of gelatin provokes a significant 
improvement in the compressive strength. (Bigi et al 2004) Detailed structural analyses of GEL-
CP and C-CP samples carried out during the setting reaction indicate that the improvement of 
the mechanical properties are most likely due to the inhibition of crystal growth caused by the 
presence of gelatin. The apatitic crystals grown in the presence of gelatin display reduced 
crystallinity and mean dimensions, which yields to a closely packed microstructure and to a 
reduced total porosity. Furthermore, the presence of gelatin should ensure a better distribution 
of the mechanical load that should contribute to the improvement of the mechanical 
properties.  
In the present thesis in vitro biological investigations were conducted to investigate the 
biocompatibility properties of this new bone cement enriched with gelatin in comparison with 
traditional cements. To this purpose the effect of biomaterials on osteoblast cell line MG63 
proliferation, activation and differentiation were evaluated. 
The osteoblast proliferation measured by WST-1 assay showed significantly higher value for 
osteoblasts grown on GEL-CP when compared to C-CP, at every experimental time. This result 
shows that gelatin added to the cement positively affects cell viability. 
Moreover, to investigate the effect of biomaterials on cell activationand differentiation, ALP, 
CICP and OC were selected. The comparison of the results obtained on GEL-CP and on C-CP 
indicates that the presence of gelatin stimulated ALP and CICP production. OC was not affected 
by the presence of gelatinand the level of this protein was not different from the one of the 
control.  Increase in TGF-ß1 production was noted in the GEL-CP group in comparison with C-CP 
group. This result indicates thatgelatin stimulates osteoblasts to express TGF-ß1, whichmay 
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accelerate matrix synthesis.To improve data on cytotoxicity Interleukin-6 (IL-6) was also 
measured. The current findings showed an initial enhancement of IL-6 at 3 days. The values 
were reduced to lower level in the longer experimental times. The results obtained from the 
other tested parameters demonstrate that both C-CP and GEL-CP did not stimulate an over-
expression of the inflammatory cytokine, and did not induce altered bone turnover.  
Regarding SEM analysis,it was demonstrated that biomaterials did not alter osteoblast 
morphology and confirmed the better cell response to GEL-CP than to C-CP. 
Measurement of microhardness showed that untreatedGEL-CP samples had lower HV degree 
values when compared to untreated C-CP samples, but after contact with cell culture medium 
up to 21 days, GEL-CP samples showed statistically higher values in comparison with C-CP 
samples. It seems that the presence of gelatin enhances the hardness of cement when treated 
with in DMEM for 3 weeks. 
In conclusion, these in vitro results showed that the addition of gelatin to calcium phosphate 
cement induced the improvement of biological properties of the biomaterial. In fact GEL-CP 
xhibited enhanced osteoblast activation and extra-cellular matrix mineralization processes 
when compared to C-CP.These in vitro results suggest that GEL-CP is a promising biomimetic 
material to be successfully applied as bone substitute.To this purpose, an in 
vivoinvestigationwas performed to evaluate the in vivo behavior of this new biomaterial. 
As with any experimental investigation, and particularly in animal testing, the validity of the 
experimental model for the question being researched is of decisive importance for the 
evaluation of the test results. In order to be able to study the stimulating effect of bone 
regeneration of various implantation materials, the investigation have to be performed on an 
animal model. (Kattagen BD 1987) The histologic study and the static and dynamic 
histomorphometric measurements carried out on the femoral condyle of rabbits allowed the 
evaluation of bone characteristics and quality. 
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At 4-weeks HA implant had significantly higher value of healing rate than GEL-CP implant.No 
significant differences were observed in the osseointegration index (BIC) between C-CP, GEL-CP 
and HA groups. Moreover, dynamic histomorphometry showed significantly higher value of 
MAR and BFR/BS in C-CP implant in comparison to GEL-CP implant and HA implant. 
At 12-weeks the healing rate showed significantly higher value in HA implants in comparison to 
C-CP implants and in comparison to GEL-CP implants. Moreover, as at 4-weeks, also 12 weeks 
after surgery there were no significant differences in the osseointegration index (BIC) between 
C-CP, GEL-CP and HA groups. Dynamic histomorphometry does not show any significant 
differences among the experimental groups. 
Thesein vivo results have allowed to hypothesize that an improvement in the structure of this 
novel material would lead to a greater upgrading in the in vivo experimental study.In fact, 
successful use of implants requires materials exhibiting specific characteristics particular to the 
application. As said earlier the first characteristic was the biocompatibility but the second is the 
demonstration of appropriate functional characteristics. The histological images suggest that 
“bulk” experimental biomaterials were implanted in the confined bone defects and therefore 
future studies will be focused on the improvement of biomaterials porosity. 
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8. STRONTIUM-DOPED HYDROXYAPATITE NANOCRYSTALS AND ALENDRONATE-DOPED 
HYDROXYAPATITE NANOCRYSTALS 
8.1 Introduction 
The inorganic phase of bone is a basic calcium phosphate assimilated to the synthetic HA 
Ca10(PO4)6(OH)2, HA. The high stability and flexibility of apatite structure justifies the great 
variety of possible cationic and anionic substitutions, and the presence of a number of foreign 
ions associated to biological apatites. (Elliott JC1994) 
Sr is present in the mineral phase of bone, especially at the regionsof high metabolic turn-over 
(Blake GM 1986); its content in a new compact bone is three- to four-fold higher than in anold 
compact bone, and approximately 2.5-fold higher in new than in old cancellous bone.(Marie PJ 
2001) Furthermore,Sr administration as Sr ranelate has recently been shown to reduce the 
incidence of fracturesin osteoporotic patients.(Marie PJ 2005, Ammann P 2005) Sr exerts both 
antiresorbing and bone forming effects in vitro, because it increases the number of osteoblasts 
and decreases the number and the activity of osteoclasts.Again, Sr administration has been 
shown to induce a significant increase in bone mass and bone strength by a dual mechanism of 
action: inhibition of bone resorption and augmentation of bone formation in both normal and 
ovariectomized animals.(Ammann P 2004) Clinical studies indicate that Sr increases bone 
formation and tends to decrease bone resorption in treated osteoporotic patients.The growing 
evidence of the beneficial effect of Sr on bone justifies the increasing interest toward Sr 
incorporation in calcium phosphate bioceramics and cements.(Landi E 2007, Panzavolta S 
2008)In vitro studies indicated that Sr-containing calcium phosphate ceramics enhance 
proliferation and differentiation of osteoblast cells.(Xue W 2006)Furthermore, it was reported 
that Sr-containing HA injectable cements provide good osteointegration in the cancellous 
bone.(Camire' CL 2005)Because of its similarity with bone mineral and high biocompatibility, 
synthetic HA attracts great interest as a biomaterial. However, synthetic HA is usually employed 
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in the shape of sintered coarse particles, which have crystal size and shape quite different from 
those of biological apatites. As a matter of fact, one of the most striking peculiarities of 
biological apatites is their small crystal sizes, of the order of tens of nanometers. It has been 
suggested that better osteoconductivity would be achieved if HA were more close to bone 
mineral in crystal structure, crystal size, and morphology.(Pezzatini S 2006)A better response 
might be achieved by enriching HA composition with a biologically active ion, such as Sr. Sr can 
replace calcium in the HA structure in the whole range of composition, inducing a linear 
variation of the lattice constants. 
Recently, an increasing body of literature has suggested that also BPs have become one of the 
most widely used drugs in the treatment of osteoporosis; they significantly reduce the risk of 
new fractures in women with postmenopausal osteoporosis. (Chesnut III C 2004, McClung MR 
2001) BPs display a common backbone structure of P–C–P, where C is carbon and each P is a 
phosphonate group. The two phosphonate groups are essential both for binding to HA and for 
the biochemicalmechanism of action. Individual BPs are characterized by the two covalently 
bonded side chains attached to the central carbon atom, termed R1 and R2, which determine 
the efficiency of the compound. Binding to bone is enhanced when R1 is a hydroxyl group, 
whereas the R2 side group has some effect on binding but predominantly determines the 
antiresorptive potency of the BPs. In particular, the R2 side chain of nitrogen-containing BPs, N-
BPs, can also influence overall bone affinity as a result of the ability of the nitrogen moiety to 
interact with the crystal surface of bone mineral. (Coxon FP 2006, Nancollas GH 2006, 
Papapoulos SE 2006) The presence of nitrogen groups within the R2 side group is associated 
with the ability of an individual BP to inhibit farnesyl pyrophosphate (FPP) synthase, a major 
enzyme in the mevalonate pathway. As a result, many of the activities of the osteoclasts are 
disrupted, including migration, attachment, and resorption, and ultimately, cell death can occur 
via apoptosis. (Russell RGG 2007) Nevertheless, literature hassuggested that BP use, especially 
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intravenous preparations, may be associated with osteonecrosis of the jaws. Thus, some 
experts caution that the benefits of prolonged use ofBPs must be carefully weighed against the 
potentialnegative effects of over suppression of bone metabolism. (Ott SM 2001, 2005) On this 
basis, the development of strategies for localadministration of BPs becomes even more 
interesting.  
This thesis is aimed to evaluate the influence of Sr and AL substitution to calcium into HA 
structure on the in vitroand in vivo response of bone cells. For this purpose we have carried out 
an in vitro study on cultures of osteoclast and osteoblast grown on HA nanocrystals synthesized 
at different extent of Srand AL substitution for calcium and an in vivo study in order to 
examinate the fusion rates in intact female of rats as well as ovariectomized estrogen-deficient 
female rats using these two alternative bone graft materials. 
The use of ovariectomized animals is a recognized model for estrogen depletion and following 
osteoporosis; in fact ovariectomized rats show a significant decrease in bone mineral density. 
(Davidge ST 2001) Bone loss in this model shares many similarities with bone loss in early 
postmenopausal women, including an increase in bone turnover with bone resorption in excess 
of formation. (Sakakura Y 2001) Studying the effect of spinal fusion in a model of osteoporosis 
has high clinical potential because many patients who undergo spinal fusion surgery have 
osteoporotic bone disease.  
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8.2 Materials and methods 
8.2.1 Tested materials-Strontium-doped hydroxyapatite nanocrystals- structural and mechanical 
characterization 
The synthesis ofHA nanocrystals was carried out in N2 atmosphere by dropwise addition of 50 
mL of 0.65M (NH4)2HPO4 solution, at pH 10 adjusted with NH4OH, to 50 mL of 1.08M Ca(NO3)2 
4H2O solution at pH adjusted to 10 with NH4OH. The precipitate was maintained in contact with 
the reaction solution for 5 h at 90°C under stirring, then centrifuged at 10,000 rpm for 10 min 
and repeatedly washed with CO2-free distilled water. The product was dried at 37°C overnight. 
Sr-substituted HAs were synthesized by preparing the nitrate solution using the appropriate 
amounts of Ca(NO3)2 4H2O and Sr(NO3)2. Different compounds were prepared from solutions 
containing 0, 3, 5, and 10 Sr atom % ([Sr/(Ca þ Sr)] 3 100), and were labelled Sr0, Sr3, Sr5, and 
Sr10, respectively. 
X-ray diffraction analysis was carried out by means of a PANalytical X’Pert PRO powder 
diffractometer equipped with a monochromator in the diffracted beam. Cu Kα radiation was 
used (40 mA, 40 kV).  
Calcium and Sr contents were determined using a GBC 901 atomic absorption 
spectrophotometer (λ(Ca) 5 422.7 nm; λ(Sr) 5 460.7 nm). The samples were diluted to an 
appropriate volume with 10% lanthanum in 50% HCl, to suppress interferences. 
For TEM investigations, a small amount of powder was dispersed in ethanol and submitted to 
ultrasonication. A drop of the calcium phosphate suspension was transferred onto holey carbon 
foils supported on conventional copper microgrids. A Philips CM 100 transmission electron 
microscope operating at 80 kV was used. 
The surface area was measured using a Carlo Erba Sorpty 1750 BET analyzer using constant 
volume N2 absorption with desorption at 100°C. 
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For cell experiments, disk-shaped samples were prepared by pressing the powders into 
cylindrical molds. The disks were sterilized with gamma rays. 
8.2.2 Tested materials-Alendronate-doped hydroxyapatite nanocrystals-structural and 
mechanical characterization 
50 ml of 1.08M Ca(NO3)2 _4H2O solution at pH adjusted to 10 with NH4OH was heated at 90 °C 
in N2 atmosphere and 50 ml of 0.65M (NH4)2HPO4 solution, pH 10 adjusted with NH4OH, was 
added drop wise under stirring. Soon after completion of the phosphate addition, the AL 
solution was dropped under stirring in the reaction vessel. The precipitate was maintained in 
contact with the reaction solution for 5 h at 90 °C under stirring, then centrifuged at 10,000 
rpm for 10 min and repeatedly washed with CO2-free distilled water. The product was dried at 
37 °C overnight. Four series of samples (HA, HA–AL7, HA–AL14, and HA–AL28) were prepared 
using AL concentrations of 0, 7, 14 and 28 mM.  
X-ray diffraction analysis was carried out by means of a PANalytical X’Pert PRO powder 
diffractometer. CuKα radiation was used (40 mA, 40 kV). Data were obtained in the range of 2y 
from 101 to 1001 (0.0201/ step, 10 s/step). The lattice parameters were determined using 
Debvin, a program essentially implemented on Rietveld routine.  
AL content was determined spectrophotometrically via complex formation with Fe(III) ions 
using a Varian Cary50Bio instrument (λ=290 nm). AL content of HA–AL7, HA–AL14, and HA–
AL28 was 3.9, 6.2 and 7.1 wt%, respectively.  
For cell experiments disk shaped samples were prepared by pressing the powders into 
cylindrical moulds. Cell experiments were carried out on gamma rays sterilized disks of HA–AL7, 
HA–AL14, HA–AL28, and HA as reference. 
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8.2.3 In vitro study: Strontium-doped hydroxyapatite nanocrystals 
Osteoblast culture. MG-63 human osteoblast-like cells were cultured in DMEM medium (Sigma, 
UK) supplemented with 10% FBS and antibiotics (100 U/mL penicillin, 100 mg/mL 
streptomycin). Cells were detached from culture flasks by trypsinization, washed, and cell 
number and viability were hecked with trypan blue dye exclusion test. MG-63 osteoblast-like 
cells were plated at a density of 2 X 104cells/mL/well in 24-well plates containing sterile 
samples of Sr0, Sr3, Sr5, and Sr10. The same concentration of cells was seeded in empty wells 
for control (CTR). Plates were cultured in standard conditions, at 37°C with 95% humidity and 
5% CO2 up to 21 days. At 24 h medium was changed with DMEM additioned with b-
Glicerophosphate (10-8 nM) and Ascorbic acid (50ng/ml) to activate osteoblasts. For the 
production of osteocalcin the culture medium was enriched with 1,25(OH)2D3, 48 h before the 
end of experimental time. 
Osteoblast proliferation and activity. Cell proliferation and viability (3, 7, 14, and 21 days) was 
determined by WST1 (WST1, Roche Diagnostics GmbH, Manheim, Germany) colorimetric 
reagent test. The assay is based on a tetrazolium salt that is reduced to a soluble formazan salt 
by a reductase of the mitochondrial respiratory chain, which is active only in viable cells. One 
hundred microliters of WST1 solution and 900 µL of medium (final dilution: 1:10) were added to 
the cell monolayer, and the multiwell plates were incubated at 37°C for further 4 h. 
Supernatants were quantified spectrophotometrically at 450 nm with a reference wavelength 
of 640 nm. Results of WST1 are reported as optical density (OD) that directly correlates with 
the cell number. At the end of experimental times the supernatant was collected from all wells 
and centrifuged to remove particulates, if any. Aliquots were dispensed in Eppendorf tubes for 
storage at -80°C and assayed for: 
-Type I Collagen (CICP, Prolagen-C enzyme Immunoassay kit, Metra Biosystem, CA)(previously 
described); 
93 
 
-Alkaline phosphatase activity (ALP, Immunoassay kit, Metra Biosystem, CA)(previously 
described); 
-Osteocalcin (OC, Osteocalcin Instant Elisa, Bender MedSystems, Wien, A)(previously 
described).  
The measured concentration and activity were normalized by cell proliferation to take into 
account the differences in cell growth. 
Osteoclast culture. Peripheral human blood, obtained from healthy adult volunteers, was 
collected in heparinated tubes. A volume of peripheral blood was diluted 1:1 with prewarmed 
PBS and carefully layered on an equal volume of Histopaque1077. Density gradient 
centrifugation (400g at 20°C for 30 min) was used to separate the mononuclear cells from the 
other elements of blood. After centrifugation, the mononuclear cells accumulated at the 
interface between PBS and Histopaque were collected, washed, resuspended in 1 mL of culture 
medium (DMEM + 10% FBS), and counted (Trypan-blue exclusion dye in a Neubauer chamber). 
Then cells were plated on thin slides (Ø 10 mm) of ovine cortical bone as control (CTR), and 
samples of Sr0, Sr3, Sr5, and Sr10 in 24- well culture plates and incubated at 37°C in 5%CO2 for 
90 min. After 24 h the non-adherent cells were washed off to dispose the culture of 
contaminating lymphocytes, so that only the adherent monocytes were used for culture and 
the medium was replaced with osteoclast differentiation medium (DMEM + 10% FBS + 10-7M 
PTH, 25 ng/mL MCSF, 30 ng/mL RANKL). Cells were cultivated for up to 21 days. After 1 week, 
the control bone was used only to assess the differentiation and activation of osteoclasts using 
TRAP assay (multinucleated cells positive for tartrateresistant acid phosphatase) and pit assay 
(resorbed area from bone slices), which are markers of osteoclast formation and activity. TRAP-
staining of cells cultured on CTR bone slides was done, exactly according to manufacturer’s 
instructions (SIGMA, Buchs, Switzerland). The positive cells developed red color of different 
intensities. For measurement of resorbed area in the pit-assay, bone slides with cultured cells 
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were washed with PBS, incubated in 5% sodium hypochlorite for 10 min, washed twice 
withwater, and stained with 0.1% toluidine blue. The pits developed blue to purple color. On 
experimental samples, WST1 test was performed to assess cell proliferation after 21 days of 
culture. 
Osteoclast morphology. Samples for each material, at the end of experimental time, were 
processed for scanning electron microscopy (SEM): osteoclasts grown on the materials were 
fixed in 2.5% glutaraldehyde, in 0.01M phosphate buffer pH 7.4 for 1 h and dehydrated in a 
graded ethanol series. After a passage in hexamethyldisilazane, the samples were air dried. The 
samples were sputter-coated with Pt/Pd alloy prior toexamination with a Philips XL20 scanning 
electron microscope operating at 15 kV. 
8.2.4 In vitro study: Alendronate-doped hydroxyapatite nanocrystals 
Osteoblast culture. MG-63 human osteoblast-like cells were cultured in DMEM medium (Sigma, 
UK) supplemented with 10% FBS, and antibiotics (100 U/ml penicillin, 100 mg/ml 
streptomycin). Cells were detached from culture flasks by trypsinization, washed, and cell 
number and viability were checked with trypan blue dye exclusion test. MG-63 osteoblast-like 
cells were plated at a density of 2x104cells/ml/well in 24-well plates containing sterile samples 
of HA, HA–AL7, HA–AL14, and HA–AL28. The same concentration of cells was seeded in empty 
wells for control (CTR). Plates were cultured in standard conditions, at 37±1° C with 95% 
humidity and 5% CO2 up to 21 days. At 24 h medium was changed with DMEM additioned with 
b-glicerophosphate (10-8 nM) and Ascorbic acid (50 mg/ml) to activate osteoblasts. For the 
production of osteocalcin the culture medium was enriched with 1,25(OH)2D3 48 h before end 
of experimental time. 
Osteoblast proliferation and activity. Cell Proliferation Reagent WST-1 test was done to assess 
cell proliferation and viability (3, 7, 14 and 21 days): 100 ml of WST1 solution and 900 ml of 
medium (final dilution: 1:10) were added to the cell monolayer, and the multi-well plates were 
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incubated at 37 °C for further 4 h. Supernatants were quantified spectrophotometrically at 450 
nm with a reference wavelength of 640 nm. Results of WST1 are reported as optical density 
(OD).At the end of the experimental times the supernatants were collected from all wells and 
centrifuged to remove particulates, if any. Aliquots were dispensed in Eppendorf tubes for 
storage at -70 °C and assayed for: 
-Type I collagen (CICP, Prolagen-C enzyme Immunoassay kit, Metra Biosystem, CA, USA); 
(previously described); 
-Matrix Metalloproteinase-1 (MMP-1, Elisa immunoassay, R&D Systems, MN, USA) and Matrix 
Metalloproteinase-13 (MMP-13, Elisa immunoassay, R&D Systems, MN, USA). MMP-1 and 13 
are proteins of the matrix metalloproteinase (MMP) family and are involved in the breakdown 
of extracellular matrix in normal physiological processes, such as embryonic development, 
reproduction, and tissue remodeling, as well as in disease processes.  
-Osteoprotegerin (OPG, Osteoprotegerin Instant Elisa, Instant Elisa, Bender MedSystems, Wien, 
A)OPG is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor 
superfamily.Recombinant human osteoprotegerin specifically acts on bone, increasing bone 
mineral density and bone volume.  
-Tumor necrosis factor-related activation-induced cytokine (TNF-α, Trance Instant Elisa, Bender 
MedSystems, Wien, A). TNF-α is a pleiotropic cytokine yhat plays a central role in inflammation 
and apoptosis; in the bone tissue induces bone resorption by stimulating the production of 
osteoclasts. 
Alkaline phosphatase activity (ALP, Immunoassay kit, Metra Biosystem, CA, USA), and 
Osteocalcin (OC, Osteocalcin Instant Elisa, Bender MedSystems, Wien, A)(previously described), 
were tested on supernatants immediately after collection. The measured concentration and 
activity were normalized by cell number to take into account the differences in cell growth. 
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Osteoblast morphology. Samples for each material, at the end of experimental times, were 
processed for scanning electron microscopy (SEM): osteoblasts grown on the materials were 
fixed in 2.5% glutaraldehyde, in pH 7.4 phosphate buffer 0.01M for 1 h and dehydrated in a 
graded ethanol series. After a passage in hexamethyldisilazane, the samples were air-dried. The 
samples were sputter-coated with Pd/Au prior to examination with a Philips XL-20 Scanning 
Electron Microscope operating at 15 kV. 
Osteoclast culture. Peripheral human blood was obtained from healthy adult volunteers. To 
prevent clotting blood was collected in heparinated tubes. Density gradient centrifugation was 
used to separate the mononuclear cells from the other elements of blood. Briefly, a volume of 
peripheral blood was diluted 1:1 with pre-warmed PBS and carefully layered on an equal 
volume of Histopaque1077 in a 50ml tube. The tube was centrifuged with 400g at 20 °C for 30 
min. After centrifugation, the mononuclear cells accumulated at the interface between PBS and 
Histopaque were collected and transferred to another tube. Ten milliliter of PBS were added 
and tube was centrifuged with 250g at 20 1C for 10 min. Pellet was resuspended in 1ml of 
culture medium (DMEM+10% FBS). Trypan-blue method was used to assess viability and to 
count cells in a Neubauer chamber. Then cells were plated on thin slides (Ø 10mm) of bone 
(CTR), HA, and HA–AL composite nanocrystals in a 24 wells culture plate and incubated at 37 °C 
in 5%CO2 for 90 min. Then medium was gently washed out and replaced with osteoclast 
differentiation medium (DMEM+10% FBS+10-7M PTH, 25 ng/ml M-CSF, 30 ng/ml RANKL). After 
24 h the non-adherent cells were washed off to dispose the culture of contaminating 
lymphocytes, so that only the adherent monocytes were used for culture. Cells were cultivated 
up to 14 days. After 1 week TRAP-staining of cells was done, exactly according to 
manufacturer’s instructions (SIGMA, Buchs, Switzerland) to assess osteoclast phenotype on CTR 
samples. The positive cells developed red color of different intensity. For measurement of 
resorbed area in the pit-assay, at the end of experimental time, samples of slides with cultured 
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cells were washed with PBS, incubated in 5% sodium hypochlorite for 10 min, washed twice 
with water and stained with 0.1% toluidine blue. The pits developed blue to purple color. At 14 
days cells were detached and counted to assess osteoclast viability and proliferation. 
8.2.5 Statistical analyses 
Statistical evaluation of data was performed using the software package SPSS/PC+ Statistics TM 
10.1 (SPSS Inc., Chicago, IL, USA). The experiment was repeated three times and the results 
presented are the mean of the triplicate values. Data are reported as mean7standard 
deviations (SD) at a significance level of p<0.05. After having verified normal distribution and 
homogeneity of variance, a one-way ANOVA was done for comparison between groups. Finally, 
the Scheffe´’s post hoc multiple comparison tests were performed to detect significant 
differences between groups. 
8.2.6 In vivo study: strontium-doped hydroxyapatite nanocrystals and alendronate-doped 
hydroxyapatite nanocrystals 
All surgical procedures were performed according to European and Italian legislation on animal 
experimentation and the ethical principles stated in the “Guide for the Care and Use of 
Laboratory Animals”. The study protocol was approved by the Scientific Technical Committee 
and Ethical Committee of Rizzoli Orthopedic Institute, and by the Italian Health Ministry. 
Fifty female Sprague-Dawley rats, 3 months old and 450±50g, were housed under controlled 
conditions (room temperature 20±0.5 °C; relative humidity 55±5%; 12 hours light and 12 hours 
darkness) and were supplied with 250g/rat/wk food and water ad libitum.  
Under general anesthesia (87 mg/Kg of ketamine and 13 mg/Kg of xilazine), twenty-five rats 
underwent bilateral ovariectomy by dorsal approach (Ovx Group). The remaining twenty-five 
rats were used as a control (Control group).  
Twelve weeks after ovariectomy both the animal, OVX andControl, underwent a spinal fusion. 
The animals were anesthetized with use of a combination of ketamine (87 mg/Kg) and xilazine 
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(13 mg/Kg). A posterior midline incision was made over the caudal portion of the lumbar spine. 
Two separate fascial incisions were made 3 mm from the midline. A muscle-splitting approach 
was used lateral to the facet joint to expose the transverse processes of L4 and L5. The 
experimental biomaterials were implanted between the transverse processes bilaterally. The 
fascia and skin incision were closed with use absorbable suture. Analgesics and antibiotic were 
prescribed in the immediate postoperative period. Eight weeks after materials implantation, 
the animals were euthanized and lumbar spine specimens were removed. 
The animals were divided in five groups; each group was divided in two sub-groups: Control and 
OVX. The following materials were tested: 
-Group 1: HA. 
-Group 2: SrHA 5%. 
-Group 3: SrHA 10%. 
-Group 4: HA-AL7.  
-Group 5: HA-AL28. 
Microcomputed tomography.All the specimens were scanned at 100 kV of source voltage and 
100 μA, with a rotation of the specimen of 180 degrees and a rotation step of 0.40 degrees. An 
aluminium filter of 0.5 mm between the source and the sample was used. The image pixel size 
was 10 μm and the scan duration was nearly one hour for every specimen (s/w Skyscan 1172 
version 1.5 build 8). The acquisition was carried out on three vertical connected and 
consecutive fields of view to obtain nearly 1500 images in TIFF format (1048X2000 pixels) for 
each sample. The reconstructions were performed using s/w NRecon (version 1.6.2.0) and the 
resulting jpg images had 2000X2000 pixels with a pixel size of 10 μm. No corrections were used 
except for the specific misalignment for each acquisition and a medium ring artefact reduction 
due to the small rotation step and the pixel size used. 
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Histology and histomorphometry. Lumbar spine specimens were explanted and fixed in 4% 
buffered paraformaldehyde for 48 hours for un-decalcified bone processing. The samples were 
then dehydrated by placing them in graded series of increasing percentage of alcohol with one 
step in 50% alcohol, one step in 75% alcohol, two steps in 95% alcohol, and two steps in 100% 
alcohol, for 48 hours per each step. Finally, they were embedded in polymethyl-methacrylate 
(Merck, Shuchardt, Hohenbrunn, Germany). Blocks were sectioned in the sagittal plane. A 
series of sections 200±100 μm thick, spaced about 300 μm apart because of the thickness of 
the microtome diamond saw, were obtained with a Leica 1600 diamond saw microtome (Leica 
SpA, Milan, Italy). The sections were then automatically thinned (EXAKT Cutting and Grinding 
Systems, GmbH & Co., Norderstedt, Germany) to 30 ± 10 μm with different abrasive papers 
(EXAKT Abrasive Disc, GmbH & Co., Norderstedt, Germany), from  300 to  2000 grit in steps of 
15 minutes each. Three sections per each sample were stained with Toluidine Blu, Acid Fuchsin, 
Fast Green, histological and histomorphometrical analyses. The histological and 
histomorphometric analyses were carried out with computerized image analysis Axio-Vision-4.6 
(CarlZeiss GmbH, Germany). Three sections for each sample were analyzed by two blinded 
investigators. The bone histomorphometric parameters were measured in accordance with the 
Histomorphometry Nomenclature by the Committee of the American Society for Bone and 
Mineral Research (Parfitt AM 1988):  
-Material Volume (Mat V/TV, %): the material area expressed as a percentage of the total tissue 
area in the sampling site and converted to a volume; 
-Bone Volume (BV/TV, %): the whole spongy bone area expressed as a percentage of the total 
tissue area in the sampling site and converted to a volume;  
- Bone surface (BS/TV, %): measure of the percentage ofspongy bone surface. 
The analyses were developed at a 2.5x magnification, sharing out the images field in four 
quadrants. 
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8.2.7 Statistical analyses 
Statistical analysis was performed using the SPSS v.21.1 software (SPSS Inc., Chicago, Illinois, 
USA). Data are reported at a significance level of p<0.05. After having verified the normal 
distribution of data, the one-way ANOVA followed by the Scheffe` post hoc multiple 
comparison test between sub-groups within each tested materials and between materials 
within each sub-groups was used to analyze histomorphometric data by considering HA as a 
reference material. 
 
8.3 Results 
8.3.1 Tested materials -Strontium-doped hydroxyapatite nanocrystals- structural and 
mechanical characterization 
The results of the powder X-ray diffraction analysis confirm that the products synthesized in the 
presence of different Sr concentrations in solution are constituted of HA as unique crystalline 
phase.  The pattern of the sample synthesized inthe absence of Sr displays well defined and 
sharp peaks in agreement with a high degree of crystallinity. The X-ray pattern obtained from 
the sample Sr5, and even more that recorded from sample Sr10, exhibit broader diffraction 
peaks. In agreement, the length of the coherent domains evaluated from the width at half 
maximum intensity decreases on increasing Sr concentration, both along the c-axis and along 
the direction perpendicular to it.  Previous results of the structure refinements, carried out 
using the Rietveld method, indicate that at low content, Sr displays a slight preference for the 
cation site M(1) of HA structure. M(1) site, where cations are aligned in columns, offers less 
room for the big Sr ion than the M(2) site arranged at the apexes of ‘‘staggered’’ equilateral 
triangles, usually preferred by ions with a ionic radius greater than calcium. This occupancy 
preference might be responsible for the reduction of the length of the perfect crystalline 
domains. Accordingly, Sr-HA nanocrystals display more perturbed shapes and ill-defined edges 
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than HA nanocrystals. However, the mean dimensions of the nanocrystals do not change 
appreciably, in agreement with the results of the specific surface area, which exhibits a mean 
value of 60m2/g. The values of the cell parameters indicate that Sr incorporation into HA 
structure provokes an enlargement of the unit cell, in agreement with its bigger dimensions. 
The observed variations are in accordance with the extent of Sr incorporated into the 
nanocrystals, which increases as a function of Sr concentration in solution up to about 7 %. 
8.3.2 Tested materials -Alendronate-doped hydroxyapatite nanocrystals-structural and 
mechanical characterization 
In agreement with previous results, the modified procedure of synthesis allows to prepare 
composite HA–AL nanocrystals at different concentration of the BP. As a matter of fact, the 
dropwise addition of the AL solution into the reaction vessel just after completing the 
phosphate solution addition prevents the precipitation of amorphous calcium phosphate, and 
induces the precipitation of HA as unique crystalline phase in the range of AL concentration 7–
28mM, as it results from the powder X-ray diffraction patterns.The slight increase of the 
broadening of the diffraction peaks on increasing AL concentration is in agreement with a 
modest decrease of the length of the crystalline domains as the AL content in the apatite 
nanocrystals increases up to 7.1%. On the basis of the results of the analysis of the composite 
nanocrystals structural modifications as a function of AL content, we suggested that the 
interaction of AL withcalcium ions of HA could occur through a bidentate chelation of 
deprotonated oxygen atoms of the BP anion without greatly affecting the crystal structure of 
HA.  
The slight structural disorder induced by AL incorporation is responsible of the observed 
reduction of the thermal stability of the composites. In fact, heat treatment induces a partial 
conversion of HA–AL nanocrystals into β-tricalcium phosphate (β-TCP). The extent of 
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conversion increases as a function of AL content, so that the X-ray pattern of the sample HA–
AL28 after heat treatment at 1100 °C reveals the co-presence of HA, β-TCP, and α-TCP. 
8.3.3 In vitro study: Strontium-doped hydroxyapatite nanocrystals 
Cell proliferation and markers of osteoblast synthetic activity were tested to evaluate 
osteoblasts behavior when cultured on Sr-HA at different Sr contents. Osteoblast proliferation 
increases up to 14 days, and then it decreases. No significant difference was found among all 
groups at 7 and 21 days, whereas in the other experimental times osteoblasts cultured on Sr10 
showed significantly greater proliferation when compared to Sr0. In brief, cells grow on Sr0 
reference samples as well as on Sr3 and Sr5, whereas on Sr10 they reach statistically higher 
values (Figure 24a). ALP activity is generally higher in Sr5 and Sr10 groups than in Sr3 and Sr0 
groups. In particular, thehighest value of ALP activity was recorded for Sr10 at 14 days, whereas 
it decreases at 21 days (Figure 24b). The production of CICP was not influenced at 3 days, 
whereas at 7, 14, and 21 days CICP level was significantly higher in Sr5 and Sr10 groups when 
compared to Sr0 and Sr3 (Figure 24c). No differences were found for OC at 3 and 7 days among 
groups, but at 14 and 21 days OC was significantly higher in Sr5 and Sr10 in comparison with 
Sr0 and Sr3 groups (Figure 24d). Sr also affects osteoclast culture, as shown by the significant 
reduction of cell proliferation on Sr3, Sr5, and Sr10 samples in comparison with Sr0 (Figure 25). 
SEM images show cells with the typical features of functional osteoclasts. Osteoclasts grown on 
Sr0 are large, flat cells with a ruffled border (characteristic morphology of osteoclasts grown in 
vitro), as shown in Figure 26 (a). These cells are polymorphic, suggesting active motility, and 
have some vesicles associated with the ruffled border. Osteoclast grown on Sr containing 
samples generally show less filopodia and develop less ruffled borders, suggesting an inhibitory 
effect of Sr on the bone-resorbing activity, as it can be observed in Figure 26 (b,c) for Sr5 and 
Sr10, respectively. 
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Figure 24: Proliferation, differentiation, and synthetic activity of MG63 after 3, 7, 14, and 21 
days of culture on samples of Sr0, Sr3, Sr5, and Sr10. Mean, n 5 6 triplicates (*p<0.05; 
**p<0.005; ***p<0.0005). (a) WST1: 3 and 14 days, *Sr10 versus Sr0; 7 and 21 days, n.s. (b) 
ALP: 3 days, *Sr3, Sr10 versus Sr0; 7 days, **Sr5, Sr10 versus Sr0, Sr3; 14 days, **Sr5 versus Sr0, 
Sr3; ***Sr10 versus Sr0, Sr3; 21 days, *Sr5 versus Sr0, Sr3, Sr10. (c) CICP: 3 days, n.s.; 7 days, 
*Sr5, Sr10 versus Sr0, Sr3; 1 days, *Sr5 versus Sr0, Sr3 and **Sr10 versus Sr0, Sr3; 21 days, 
**Sr5, Sr10 versus Sr0, Sr3. (d) OC: 3 and 7 days, n.s.; 14 days, **Sr10 versus Sr0, Sr3, Sr5; 21 
days, **Sr5, Sr10 versus Sr0, Sr3. 
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Figure 25: Proliferation of osteoclast after 21 days of culture on samples Sr0, Sr3, Sr5, and Sr10. 
Mean, n 5 6 triplicates (*p<0.05; **p<0.005; ***p<0.0005). WST1: *Sr3, Sr5 versus Sr0; ** Sr10 
versus Sr0. 
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Figure 26: SEM images of human osteoclasts cultured on Sr0 (a), Sr5 (b), and Sr10 (c). Bars = 10 
µm. 
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8.3.4 In vitro study: Alendronate-doped hydroxyapatite nanocrystals 
AL incorporation into HA nanocrystals affects in vitro cell response. AL improves osteoblast 
proliferation, as it results from the values reported in Figure 27. At 3 days there were no 
differences among all groups, whereas at 7 days all biomaterials containing AL showed 
significantly higher values when compared to CTR and HA groups (p<0.005). The difference was 
maintained at 14 (p<0.0001) and 21 (p<0.05) days also. HA groups was significantly higher than 
CTR (p<0.0001) at 14 days only. In agreement with proliferation data, cells attachment and 
spreading increase in the presence of AL, and the cells appear more flattened and display many 
more filopodia than those grown on control HA (Figure 28a,b). 
 
 
Figure 27: Osteoblasts proliferation after 7, 14 and 21 days of culture on samples of HA–AL7, 
HA–AL14, HA–AL28, HA as reference, and polystyrene of cell culture plate as CTR. Mean, n = 6 
triplicates. Scheffe` post hoc multiple comparison test (*p<0.05; **p<0.005; ***p<0.0001): 3 
days, ns; 7 days: **CTR and HA versus HA–AL7, HA–AL14, HA–AL28; 14 days: ***CTR versus HA, 
HA–AL7, HA–AL14, HA–AL28; 21 days: *HA versus HA–AL7, HA–AL14, HA–AL28. 
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Figure 28: SEM images of human osteoblasts MG63 on (a) HA, and (b) HA–AL28 after 7 days of 
culturing. Bars = 100 microns. 
 
At all experimental times MG63 cells showed significantly higher level of ALP and CICP on the 
HA–AL surfaces, when compared to CTR, and even compared to HA when cultured on HA–AL14 
and HA–AL28. In particular, ALP activity (Figure29a) of CTR group was always significantly lower 
than the other groups (p<0.0001). Moreover, when compared to HA, ALP activity was 
significantly higher in HA–AL14 and HA–AL28 groups at 7 days (p<0.005) and 21 days 
(p<0.0001), and in HA–AL7, HA–AL14, and HA–AL28 at 14 days (p<0.0001).No significant 
difference in OC production was observed at 3 days on the different samples. At variance, 
osteocalcin production (Figure 29b) at 7 days was significantly higher in HA–AL14 (p<0.0001) 
and HA–AL28 (p<0.005) when compared to other groups, while at both 14 and 21 days HA–AL7, 
HA–AL14, and HA–AL28 reached significative higher level (p<0.0001). The beneficial effect of AL 
on osteoblast differentiation is confirmed by the results obtained on collagen type I level 
(Figure29c), which was significantly higher in all experimental groups when compared to CTR at 
3 (p<0.005), 7, 14 and 21 days (p<0.0001) and to HA at 7, 14 (p<0.0001) and 21 days (p<0.05). 
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Figure 29: Osteoblast differentiation, and synthetic activity after 7, 14 and 21 days of culture on 
biomaterial samples and CTR. Mean, n = 6 triplicates. Scheffe` post hoc multiple comparison 
test (*p<0.05; **p<0.005; ***p<0.0001). (a) ALP: 3 days, ***CTR versus HA, HA–AL7, HA–AL14, 
HA AL28; 7 days, ***CTR versus HA, HA–AL7, HA–AL14, HA–AL28; **HA versus HA–AL14, HA–
AL28; 14 days, ***CTR versus HA, HA–AL7, HA–AL14, HA–AL28; ***HA versus HA–AL7, HA–
AL14, HA AL28; 21 days, ***CTR versus HA, HA–AL7, HA–AL14, HA–AL28; ***HA versus HA–
AL14, HA–AL28. (b) OC: 3 days, ns; 7 days, ***HA–AL14 and **HA–AL28 versus CTR, HA, HA–
AL7; 14 days, ***CTR and HA versus HA–AL7, HA–AL14, HA–AL28; ***CTR versus HA; 21 days, 
***CTR and HA versus HA–AL7, HA–AL14, HA–AL28. (c) CICP: 3 days, **CTR versus HA, HA–AL7, 
HA–AL14, HA–AL28; 7 days, ***CTR and HA versus HA–AL7, HA–AL14, HA–AL28; ***HA versus 
CTR; ***HA–AL7 versus HA–AL14, HA–AL28; 14 days, ***CTR and HA versus HA–AL7, HA–AL14, 
HA–AL28; ***HA versus CTR; ***HA–AL7 versus HA–AL14, HA–AL28; 21 days, ***CTR versus 
HA, HA–AL7, HA–AL14, HA–AL28; *HA versus HA–AL7, HA–AL14, HA–AL28. 
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The levels of osteoprotegerin/Trance ratio of the different samples do not display significant 
differences among the groups (Figure 30). 
 
 
Figure 30: Osteoprotegerin/Trance ratio of the different samples. 
 
MMPs values reported in the study were never higher than CTR (Figure 31a, b). At the highest 
concentration of AL, osteoblast showed a significant decrease of both metalloproteinase 
production (p<0.05 and p<0.0001, respectively). 
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Figure 31: Matrix-metalloproteinase evaluation after 14 days of culture on biomaterial samples 
and CTR. Mean, n = 6 triplicates. Scheffe` post hoc multiple comparison test (*p<0.05; 
**p<0.005; ***p<0.0001). (a) MMP-1: *HA–AL28 versus CTR, HA, HA–AL7, HA–AL14. (b) MMP 
13: ***HA–AL28 versus CTR, HA, HA–AL7, HA–AL14. 
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TRAP staining and Pit assay performed on control bone to assess osteoclast phenotype were 
positive and confirmed that the cells were differentiated. The counting of osteoclasts after 14 
days of culture on bone or on the different samples reported in Figure 32 confirms the 
inhibitory effect of AL on osteoclasts proliferation. The number of osteoclasts appears 
significantly reduced in HA–AL14 (-17%, -22%, -21%), and HA–AL28 (-29%, -33%, -31%) when 
compared to CTR, HA and HA–AL7 groups (p<0.0001). 
 
 
Figure 32: Osteoclast proliferation after 14 days from seeding on biomaterial samples and CTR. 
Mean, n=6 triplicates. Scheffe` post hoc multiple comparison test (*p<0.05; **p<0.005; 
***p<0.0001): ***HA–AL14 and HA–AL28 versus CTR, HA, HA–AL7. 
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8.3.5 In vivo study: strontium-doped hydroxyapatite nanocrystals and alendronate-doped   
hydroxyapatite nanocrystals 
All animals tolerated the operation and remained in good health during the experimental 
periods. Macroscopically there were no signs of inflammation or adverse tissue reaction. 
Histology and Histomorphometry. The evaluation of the osseous implantation by light 
microscopy showed the biocompatible behavior of tested materials. The light microscopical 
evaluation revealed a very uniform bone reaction for all specimens within the same group and 
there were evident signs of material degradation.  
In both the sub-groups, Control and OVX, of Group 1 new bone formation was observed around 
and within the HA bridging the transverse processes at8 weeks after implantation. Moreover, in 
Group 1 the OVX specimens presented thinner trabeculae, between transverse processes, than 
the Control (Figure 33a, b). At higher magnification, in both the sub-groups of Group 2 dense 
new bone was formed between the transverse process (Figure 33c,d). In sub-groups most 
surface of the HA granules was surrounded by fibrous tissue and bone ingrowth was obtained 
only in peripheral granules of the implanted HA. In Group 3 both sub-groupsshowed dense 
cancellous bone formation along the apatite in the fusion mass (Figure 33e, f).Moreover in 
Controlspecimens of Group 3 an endochondral intermediate was detectedin the fusion 
mass.Bone formation in OVX and in Controlsub-groups of Group 4 and 5 was observed around 
the transverse processes. However, in these cases due the materials degradation there was 
poor direct contact between the newly formed bone and HA enriched with different AL content 
(Figure 33e-l). 
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a  
HA OVX                                                                              
b  
HA CONTROL 
c  
SrHA5% OVX 
d  
SrHA5% CONTROL 
e  
SrHA10% OVX 
f  
SrHA10% CONTROL 
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g  
HA-AL7 OVX 
h  
HA-AL7 CONTROL 
i  
HA-AL28 OVX 
l  
HA-AL28 CONTROL 
 
Figure 33: Histological sagittal sections of the fusion mass. Toluidine Blue, Acid Fuchsin and Fast 
Green staining. Magnification 10x. a) OVX Group treated with HA;b) Control Group treated with 
HA;c) OVX Group treated with SrHA 5%; d) Control Group treated with SrHA 5%;e) OVX Group 
treated with SrHA 10%; f) Control Group treated with SrHA 10%;g) OVX Group treated with HA-
AL7; h) Control Group treated with HA-AL7;i) OVX Group treated with HA-AL28; l) Control 
Group treated with HA-AL28. 
 
The results of histomorphometrical parameters are reported in Table IV. Scheffe` post hoc 
multiple comparison testbetween sub-groups within each tested materials highlighted a 
significant difference between HA Control versus HA OVX, HA-AL28 OVX versus HA-AL28 
Control (p<0.0005 and p<0.05 respectively). In BS/TV significant difference were observed 
between HA Control versus HA OVX, HA-Sr 5% Control versus HA-Sr 5% OVX, HA-Sr 10% OVX 
versus HA-Sr 10% Control (p<0.0005, p<0.0005 and p<0.05 respectively).Moreover, Scheffè post 
doc multiple comparison test between materials within each sub-groups showed that BV/TV 
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highlighted significant higher value between Control HA and Control HA-Sr5%, Control HA-
Sr10%, Control HA-AL7, Control HA-AL28 (p<0.0005). Histomorphometrical data on OVX sub-
group showed significant increases in BV/TV of OVX HA-Sr5%, OVX HA-Sr10%, OVX HA-AL7, OVX 
HA-AL28 when compared to OVX HA (p<0.0005).  OVX HA-AL28 also showed significant higher 
values in BV/TV than OVX HA-Sr5% and HA-Sr10% (p<0.0005).  Significant higher values have 
been registered in BS/TV between Control HA and Control HA-Sr5%, Control HA-Sr10%, Control 
HA-AL7, Control HA-AL28 (p<0.0005). Moreover, Control HASr5% and Control HA-AL7 showed 
significant higher values of BS/TV when compared to Control HA-Sr10% and HA-AL28 
(p<0.0005). In addition, Control HA-AL28 highlighted significant higher value in comparison with 
Control HA-Sr10% (p<0.0005). The OVX sub-groups showed significant higher values in BS/TV 
between OVX HA-AL7 and OVX HA-Sr10%, OVX HA (p<0.005 and p<0.0005 respectively). Finally, 
OVX HA-AL28 revealed significant increases in BS/TV when compared to OVX HA, OVX HA-Sr5%, 
OVX HA-Sr10%, OVX HA-AL28 (p<0.0005). 
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Table IV: Statistical analysis of histomorphometrical measurements at 8 weeks after 
implantation. Data were expressed as Means ±  Standard Deviation. 
 
Scheffe` post hoc multiple comparison test between sub-groups within each tested materials 
(*p<0.05; **p<0.005; ***p<0.0005). BV/TV: HA Controlversus HA OVX, HA-AL28 OVX versus HA-
AL28 Control; BS/TV: HA Controlversus HA OVX, HA-Sr 5% Controlversus HA-Sr 5% OVX, HA-Sr 
10% OVX versus HA-Sr 10% Control. 
Scheffè post doc multiple comparison test between materials within each sub-groups. BV/TV: 
Control HA versus Control HA-Sr5%, HA-Sr10%, HA-AL7, HA-AL28 (ap<0.0005), OVX HA-Sr5%, 
HA-Sr10%, HA-AL7, HA-AL28 versus OVX HA (bp<0.0005), OVX HA-AL28 versus OVX HA-Sr5%, 
HA-Sr10% (cp<0.0005); BS/TV: Control HA versus Control HA-Sr5%, HA-Sr10%, HA-AL7, HA-AL28 
(dp<0.0005), Control HASr5% and HA-AL7 versus Control HA-Sr10%, HA-AL28 (ep<0.0005), 
ControlHA-AL28 versus Control HA-Sr10% (fp<0.0005), OVX HA-AL7 versus OVX HA-Sr10% 
(gp<0.005), OVX HA-AL7 versus OVX HA (hp<0.0005), OVX HA-AL28 versus OVX HA, HA-Sr5%, 
HA-Sr10%, HA-AL28 (ip<0.0005). 
 
 
 
 
 
 
 
 
 
 
Marerials BV/TV BS/TV 
CONTROL OVX CONTROL OVX 
HA 54,57 ±3,08***,a 19,60±1,58 1,90±0,02***,d 1,13±0,03 
HA-Sr5% 37,70±2,07 32,22±3,26 b 1,49±0,04***,e 1,25±0,01 
HA-Sr10% 37,76±3,90 33,23±2,40 b 0,96±0,01 1,16±0,03* 
HA-AL7 36,07±5,53 35,91±4,55 b 1,50±0,09e 1,37±0,08 g,h 
HA-AL28 34,28±3,65 46,00±4,12*,b,c 1,13±0,03f 1,67±0,07i 
119 
 
Microcomputed tomography. The Micro-CT analyses showed the presence of the implanted 
materials and of some newly formed bone between the transverse processes in the different 
experimental groups (Figure 34) and these data were confirmed by the histological and 
morphometrical analyses. 
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Figure 34: 2D micro-CT images. Presence of newly formed bone between the transverse 
processes in the different experimental groups. 
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8.4 Discussion and conclusions 
Cell proliferation and markers of osteoblast synthetic activity were tested to evaluate 
osteoblastsbehavior when cultured on Sr-HA at different Sr contents. In vitro study on Sr–HA 
nanocomposites showed that Sr substitution for Ca into HA up to about 7 atom % has a 
beneficial effect on bone cells.  Sr also affects osteoclast culture, as shown by the significant 
reduction of cell proliferation on Sr3, Sr5, and Sr10 samples in comparison with Sr0. Moreover, 
Sr concentrations in the range of 3–7 atom % significantly stimulate osteoblast activity and 
differentiation, as shown by the increased production of ALP, CICP, and OC with respect to both 
pure HA and the sample without Sr. These results are consistent with the different properties of 
the examined parameters: ALP is an early expression of a more differentiated state, osteoblast 
phenotype and differentiation, with the production of CICP, while OC is late marker of 
osteoblast differentiation. Furthermore, they indicate that the presence of Sr in the samples 
promotes osteoblast differentiation and activity. 
Also AL incorporation into HA nanocrystals affects in vitro cell response. TRAP staining and Pit 
assay performed on control bone to assess osteoclast phenotype were positive and confirmed 
that the cells were differentiated. The counting of osteoclasts after 14 days of culture on bone 
or on the different samples confirms the inhibitory effect of AL on osteoclast proliferation. 
Osteoblasts cultured on the samples at relatively high content of AL (HA–AL14 and HA–AL28) 
showed an increased production of ALP, CICP and OC with respect both to the control and to 
pure HA, without provoking abnormal collagen degradation.  ALP, CICP and OC were chosen to 
evaluate osteoblast activation and differentiation.  
The levels of osteoprotegerin/Trance ratio of the different samples do not display significant 
differences among the groups. OPG is a member of the TNF receptor family expressed by 
osteoblast and acts in the regulation of bone metabolism, and it has been shown to be a potent 
inhibitor of osteoclast differentiation and activation. Its role is linked to Trance that induces 
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osteoclastogenesis and osteoclast activation. Therefore the OPG/TRANCE ratio has a key role in 
the control of bone resorption. However, the subject is still matter of debate, since some 
Authors exclude that the inhibition of BPs on bone resorption is mediated by OPG and TRANCE 
expression whereas others stated that OPG/TRANCE changes are related to BPs treatment. 
(Dobnig H 2006, Kim YH 2005) 
 Moreover, in order to evaluate the possible cell damage after culture on experimental 
biomaterials MMP-1 and MMP-13 were measured at 14 days, when cultures reached the 
maximum level of proliferation. Matrix metalloproteinases (MMPs) play an important role in 
physiological and pathological processes including tissue remodelling, and inflammation. In 
particular MMP-1 and MMP-13 are implicated in a variety of biological processes where 
collagen degradation occurs. MMPs values reported in the study were never higher than in 
CTR.At the highest concentration of AL, osteoblasts showed a significant decrease of both 
metalloproteinase productionsindicating that no abnormal collagen degradation was 
stimulated, in agreement with the inhibitory role of BP on MMPs.(Teronen O 1999) 
These results demonstrate that AL is able to influence bone cells even in composite 
nanocrystals. 
All these data allow to suggest that Sr-doped HA and AL-doped HA could be usefully employed 
for the preparation of biomaterials capable to promote osseointegration and bone 
regeneration, and for local prevention/repair of bone loss. 
Them, based on our in vitro data we carried out anin vivo study in which the experimental 
biomaterials (HA, SrHA5%, SrHA10%, HA-AL7, HA-AL28) were implanted inlumbar spine of 
healthy and osteoporotic female rats. Ovariectomized rats are a well-established animal model 
for osteoporosis, showing both a decrease in bone mineral density, as well as reduced serum 
levels of 17-β-estradiol starting from 8 weeks after surgery. 
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Our histological studies showed that both in OVX and in control rats new bone formation was 
observed around and within the materials (HA, SrHA5%, SrHA10%, HA-AL7, HA-AL28)  bridging 
the transverse processes at sixteen weeks after implantation. Nevertheless, OVX specimens, in 
all experimental groups, presented thinner trabeculaethan the control specimens. In contrast, 
in control groups dense new bone was observed close to the spine.Moreover, in HA-AL7, HA-
AL28 groups there were poor direct contact between the newly formed bone and HA enriched 
with different AL content due the materials degradation. 
As expected our histomorphometric findings showed that in healthy bone HA was the best 
materials presenting significant higher values of BV/TV and BS/TV when compared with all the 
other experimental materials (HA-Sr5%, HA-Sr10%, HA-AL7, HA-AL28). In fact as well known, HA 
has been utilized experimentally and clinically in bone graft surgery because it is a 
biocompatible material with excellent osteoconductivity and bioactivity (Fujishiro T 2005, 
Luchetti R 2004, Matsumine A 2004). Moreover, the most unique property of this material is 
chemical similarity with the mineralized phase of bone. Contrary to healthy bone, in 
osteoporotic bone HA presented significant lower values of BV/TV and BS/TV when compared 
with all the other experimental materials (HA-Sr5%, HA-Sr10%, HA-AL7, HA-AL28); HA-AL28 
material revealed the higher values of BV/TV and BS/TV compared with all the other materials. 
In agreement with our in vitro results, in our in vivo model of osteoporosis the presences of AL 
in the composite nanocrystals inhibits osteoclast proliferation and promote osteoblast growth 
and differentiation demonstrating that the presence of AL is able to influence bone cells even in 
composite nanocrystals implantedin vivo. In our in vivo study HA-AL 28 was revealed to be a 
remarkably effective inhibitor of bone resorption in comparison to HA-Sr5%, HA-Sr10% and HA. 
In conclusions, the results of this study support the benefits of AL loaded scaffolds to facilitate 
spinal fusionosteoporotic conditions; superior fusion mass mineralization and remodeling are 
clear advantages over scaffold alone. 
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These results have allowed to detect that HA is an ideal carrier of BPs; HA loaded with 
appropriate concentration of AL may be ideal for use in spinal fusion, although the appropriate 
concentration for clinical use should be determined using large animal models.  
All the current available studies support the systems biology view that manipulating the 
implant biomaterial surface in the setting of bone growth, bone remodelling, and local 
microenvironment networks could lead to an enhanced bone healing rate in osteoporotic 
patients. However, the high costs of these delivery systems, issues of release control, the 
uncertainty concerning the most effective dosage, and the possibility of collateral effects of the 
proposed signalling molecules, are still a limitation for the use of biomaterials in clinical trials. 
Furthermore, contemporary clinical strategies that demonstrate a beneficial effect on fracture 
healing and osseointegration in healthy conditions were not investigated in pathological animal 
models and clinical osteoporotic conditions.   
The idea of an optimal bone graft substitute usable in all clinical indications, although alluring, 
is difficult to reach. Most bone graft substitutes need to be inserted into a stable host site that 
contains adequate vascularity and an adequate source of osteoblast precursor cells. In an 
appropriate site, these graft materials are eventually resorbed and replaced by host bone. It is 
often forgotten that host variables are as important as material variables. Host variables such 
as age and overall health status will have a major effect. (Williams DF, “Handbook of 
Biomaterial Properties, 1998) However, if the operative site is mechanically unstable, if there 
are inadequate cells, poor vascularity or other host factors limiting bone healing, problems may 
occur also in the presence of the ideal material. Co-morbidities of the patient, such as 
osteoporosis, will also negatively influence the in vivo performance and capacity of the 
biomaterial to incorporate through modification of the local microenvironment. Therefore, the 
bone substitute of choice depends largely on the clinical application and its associated 
biological and mechanical needs. (Beaman FD 2006) It is reasonable to assume that not all bone 
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graft substitutes will perform the same way and that the validation of a bone graft substitute in 
one clinical site may not necessarily predict its performance in another location or condition. 
(Giannoudis PV 2007) 
The large variety of bone substitutes available on the market represents not only the different 
clinical needs and scenarios encountered, but also the diversity of the expected clinical 
outcomes. The surgeon has to assess all patients’ related factors and then the requirements of 
the bone defect to be grafted, the properties needed for repair, and ultimately choose the 
appropriate bone substitute and its associated surgical technique.  
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